Background  ||| S:24 E:43 ||| NN
With  ||| S:43 E:48 ||| IN
the  ||| S:48 E:52 ||| DT
publication  ||| S:52 E:64 ||| NN
of  ||| S:64 E:67 ||| IN
the  ||| S:67 E:71 ||| DT
Antihypertensive  ||| S:71 E:88 ||| NNP
and  ||| S:88 E:100 ||| CC
Lipid-Lowering  ||| S:100 E:115 ||| NNP
Treatment  ||| S:115 E:125 ||| NNP
to  ||| S:125 E:128 ||| TO
prevent  ||| S:128 E:136 ||| VB
Heart  ||| S:136 E:142 ||| NNP
Attack  ||| S:142 E:149 ||| NNP
Trial  ||| S:149 E:163 ||| NNP
( ||| S:163 E:164 ||| -LRB-
ALLHAT ||| S:164 E:170 ||| NNP
) ||| S:170 E:171 ||| -RRB-
,  ||| S:171 E:173 ||| ,
the  ||| S:173 E:177 ||| DT
role  ||| S:177 E:182 ||| NN
of  ||| S:182 E:185 ||| IN
peripheral  ||| S:185 E:196 ||| JJ
alpha-1  ||| S:196 E:204 ||| CD
antagonists  ||| S:204 E:216 ||| NNS
in  ||| S:216 E:219 ||| IN
the  ||| S:219 E:231 ||| DT
treatment  ||| S:231 E:241 ||| NN
of  ||| S:241 E:244 ||| IN
hypertension  ||| S:244 E:257 ||| NN
has  ||| S:257 E:261 ||| VBZ
become  ||| S:261 E:268 ||| VBN
controversial ||| S:268 E:281 ||| JJ
.  ||| S:281 E:283 ||| .
The  ||| S:283 E:295 ||| DT
doxazosin  ||| S:295 E:305 ||| JJ
arm  ||| S:305 E:309 ||| NN
of  ||| S:309 E:312 ||| IN
ALLHAT  ||| S:312 E:319 ||| NNP
was  ||| S:319 E:323 ||| VBD
stopped  ||| S:323 E:331 ||| VBN
early ||| S:331 E:336 ||| RB
,  ||| S:336 E:338 ||| ,
due  ||| S:338 E:342 ||| JJ
to  ||| S:342 E:345 ||| TO
a  ||| S:345 E:355 ||| DT
doubling  ||| S:355 E:364 ||| NN
of  ||| S:364 E:367 ||| IN
the  ||| S:367 E:371 ||| DT
incidence  ||| S:371 E:381 ||| NN
of  ||| S:381 E:384 ||| IN
congestive  ||| S:384 E:395 ||| JJ
heart  ||| S:395 E:401 ||| NN
failure  ||| S:401 E:409 ||| NN
in  ||| S:409 E:420 ||| IN
this  ||| S:420 E:425 ||| DT
group ||| S:425 E:430 ||| NN
,  ||| S:430 E:432 ||| ,
as  ||| S:432 E:435 ||| RB
compared  ||| S:435 E:444 ||| VBN
to  ||| S:444 E:447 ||| TO
the  ||| S:447 E:451 ||| DT
low-dose  ||| S:451 E:460 ||| JJ
chlorthalidone  ||| S:460 E:475 ||| JJ
arm  ||| S:475 E:487 ||| NN
[  ||| S:487 E:489 ||| -LRB-
1  ||| S:489 E:491 ||| LS
]  ||| S:491 E:493 ||| -RRB-
.  ||| S:493 E:495 ||| .
Prior  ||| S:495 E:501 ||| RB
to  ||| S:501 E:504 ||| TO
this  ||| S:504 E:509 ||| DT
publication ||| S:509 E:520 ||| NN
,  ||| S:520 E:522 ||| ,
there  ||| S:522 E:528 ||| EX
had  ||| S:528 E:532 ||| VBD
been  ||| S:532 E:537 ||| VBN
no  ||| S:537 E:548 ||| DT
obvious  ||| S:548 E:556 ||| JJ
suggestion  ||| S:556 E:567 ||| NN
of  ||| S:567 E:570 ||| IN
a  ||| S:570 E:572 ||| DT
mechanism  ||| S:572 E:582 ||| NN
by  ||| S:582 E:585 ||| IN
which  ||| S:585 E:591 ||| WDT
peripheral  ||| S:591 E:610 ||| VBD
alpha-1  ||| S:610 E:618 ||| CD
antagonists  ||| S:618 E:630 ||| NNS
in  ||| S:630 E:633 ||| IN
general  ||| S:633 E:641 ||| JJ
or  ||| S:641 E:644 ||| CC
doxazosin  ||| S:644 E:654 ||| NN
in  ||| S:654 E:657 ||| IN
particular  ||| S:657 E:676 ||| JJ
would  ||| S:676 E:682 ||| MD
be  ||| S:682 E:685 ||| VB
inferior  ||| S:685 E:694 ||| JJ
to  ||| S:694 E:697 ||| TO
chlorthalidone  ||| S:697 E:712 ||| VB
or  ||| S:712 E:715 ||| CC
would  ||| S:715 E:721 ||| MD
specifically  ||| S:721 E:742 ||| RB
cause  ||| S:742 E:748 ||| VB
CHF ||| S:748 E:751 ||| NNP
.  ||| S:751 E:753 ||| .
Because  ||| S:753 E:761 ||| IN
ALLHAT  ||| S:761 E:768 ||| NNP
is  ||| S:768 E:771 ||| VBZ
an  ||| S:771 E:774 ||| DT
active-control  ||| S:774 E:789 ||| JJ
trial ||| S:789 E:794 ||| NN
,  ||| S:794 E:796 ||| ,
no  ||| S:796 E:807 ||| DT
inferences  ||| S:807 E:818 ||| NNS
can  ||| S:818 E:822 ||| MD
be  ||| S:822 E:825 ||| VB
made  ||| S:825 E:830 ||| VBN
on  ||| S:830 E:833 ||| IN
whether  ||| S:833 E:841 ||| IN
this  ||| S:841 E:846 ||| DT
increased  ||| S:846 E:856 ||| JJ
incidence  ||| S:856 E:874 ||| NN
of  ||| S:874 E:877 ||| IN
CHF  ||| S:877 E:881 ||| NNP
results  ||| S:881 E:889 ||| NNS
from  ||| S:889 E:894 ||| IN
a  ||| S:894 E:896 ||| DT
harmful  ||| S:896 E:904 ||| JJ
effect  ||| S:904 E:911 ||| NN
of  ||| S:911 E:914 ||| IN
doxazosin ||| S:914 E:923 ||| NN
,  ||| S:923 E:925 ||| ,
a  ||| S:925 E:935 ||| DT
beneficial  ||| S:935 E:946 ||| JJ
effect  ||| S:946 E:953 ||| NN
of  ||| S:953 E:956 ||| IN
chlorthalidone ||| S:956 E:970 ||| NN
,  ||| S:970 E:972 ||| ,
or  ||| S:972 E:975 ||| CC
both ||| S:975 E:979 ||| DT
.  ||| S:979 E:981 ||| .
Nonetheless ||| S:981 E:992 ||| RB
,  ||| S:992 E:1002 ||| ,
there  ||| S:1002 E:1008 ||| EX
has  ||| S:1008 E:1012 ||| VBZ
been  ||| S:1012 E:1017 ||| VBN
a  ||| S:1017 E:1019 ||| DT
large  ||| S:1019 E:1025 ||| JJ
body  ||| S:1025 E:1030 ||| NN
of  ||| S:1030 E:1033 ||| IN
literature  ||| S:1033 E:1044 ||| NN
dedicated  ||| S:1044 E:1054 ||| VBN
to  ||| S:1054 E:1057 ||| TO
the  ||| S:1057 E:1069 ||| DT
positive  ||| S:1069 E:1078 ||| JJ
effects  ||| S:1078 E:1086 ||| NNS
of  ||| S:1086 E:1089 ||| IN
peripheral  ||| S:1089 E:1100 ||| JJ
alpha-1  ||| S:1100 E:1108 ||| CD
antagonists  ||| S:1108 E:1120 ||| NNS
on  ||| S:1120 E:1131 ||| IN
surrogate  ||| S:1131 E:1141 ||| JJ
endpoints  ||| S:1141 E:1151 ||| JJ
such  ||| S:1151 E:1156 ||| JJ
as  ||| S:1156 E:1159 ||| IN
cholesterol  ||| S:1159 E:1171 ||| NN
levels  ||| S:1171 E:1178 ||| NNS
and  ||| S:1178 E:1190 ||| CC
tolerability ||| S:1190 E:1202 ||| NN
.  ||| S:1202 E:1204 ||| .
In  ||| S:1204 E:1207 ||| IN
light  ||| S:1207 E:1213 ||| NN
of  ||| S:1213 E:1216 ||| IN
the  ||| S:1216 E:1220 ||| DT
results  ||| S:1220 E:1228 ||| NNS
of  ||| S:1228 E:1231 ||| IN
ALLHAT ||| S:1231 E:1237 ||| NNP
,  ||| S:1237 E:1239 ||| ,
we  ||| S:1239 E:1250 ||| PRP
performed  ||| S:1250 E:1260 ||| VBD
a  ||| S:1260 E:1262 ||| DT
review  ||| S:1262 E:1269 ||| NN
of  ||| S:1269 E:1272 ||| IN
the  ||| S:1272 E:1276 ||| DT
literature  ||| S:1276 E:1287 ||| NN
on  ||| S:1287 E:1290 ||| IN
doxazosin ||| S:1290 E:1299 ||| NN
,  ||| S:1299 E:1309 ||| ,
terazosin ||| S:1309 E:1318 ||| NN
,  ||| S:1318 E:1320 ||| ,
and  ||| S:1320 E:1324 ||| CC
prazosin ||| S:1324 E:1332 ||| NN
.  ||| S:1332 E:1356 ||| .
Methods  ||| S:1356 E:1372 ||| NNP
Medline  ||| S:1372 E:1380 ||| NNP
and  ||| S:1380 E:1384 ||| CC
the  ||| S:1384 E:1388 ||| DT
Cochrane  ||| S:1388 E:1397 ||| JJ
databases  ||| S:1397 E:1407 ||| NN
were  ||| S:1407 E:1412 ||| VBD
used  ||| S:1412 E:1417 ||| VBN
to  ||| S:1417 E:1420 ||| TO
identify  ||| S:1420 E:1437 ||| VB
English-language  ||| S:1437 E:1454 ||| JJ
papers  ||| S:1454 E:1461 ||| NNS
on  ||| S:1461 E:1464 ||| IN
peripheral  ||| S:1464 E:1475 ||| JJ
alpha-1  ||| S:1475 E:1483 ||| CD
antagonists  ||| S:1483 E:1503 ||| NNS
in  ||| S:1503 E:1506 ||| IN
studies  ||| S:1506 E:1514 ||| NNS
targeting  ||| S:1514 E:1524 ||| VBG
cardiovascular  ||| S:1524 E:1539 ||| JJ
endpoints ||| S:1539 E:1548 ||| NN
,  ||| S:1548 E:1550 ||| ,
background  ||| S:1550 E:1569 ||| NN
physiologic  ||| S:1569 E:1581 ||| NN
literature ||| S:1581 E:1591 ||| NN
,  ||| S:1591 E:1593 ||| ,
or  ||| S:1593 E:1596 ||| CC
any  ||| S:1596 E:1600 ||| DT
studies  ||| S:1600 E:1608 ||| NNS
suggesting  ||| S:1608 E:1627 ||| VBG
mechanisms  ||| S:1627 E:1638 ||| NNS
leading  ||| S:1638 E:1646 ||| VBG
to  ||| S:1646 E:1649 ||| TO
an  ||| S:1649 E:1652 ||| DT
inferior  ||| S:1652 E:1661 ||| JJ
performance  ||| S:1661 E:1673 ||| NN
in  ||| S:1673 E:1684 ||| IN
cardiovascular  ||| S:1684 E:1699 ||| JJ
endpoints ||| S:1699 E:1708 ||| NN
.  ||| S:1708 E:1710 ||| .
Medline  ||| S:1710 E:1718 ||| NNP
was  ||| S:1718 E:1722 ||| VBD
searched  ||| S:1722 E:1731 ||| VBN
from  ||| S:1731 E:1736 ||| IN
1966  ||| S:1736 E:1741 ||| CD
to  ||| S:1741 E:1752 ||| TO
the  ||| S:1752 E:1756 ||| DT
present  ||| S:1756 E:1764 ||| JJ
with  ||| S:1764 E:1769 ||| IN
the  ||| S:1769 E:1773 ||| DT
key  ||| S:1773 E:1777 ||| JJ
words  ||| S:1777 E:1783 ||| NNS
"doxazosin ||| S:1783 E:1793 ||| RB
, ||| S:1793 E:1794 ||| ,
"  ||| S:1794 E:1796 ||| ''
"prazosin ||| S:1796 E:1805 ||| NNP
, ||| S:1805 E:1806 ||| ,
"  ||| S:1806 E:1816 ||| ''
"terazosin ||| S:1816 E:1826 ||| NNP
, ||| S:1826 E:1827 ||| ,
"  ||| S:1827 E:1829 ||| ''
"adrenergic  ||| S:1829 E:1841 ||| NNP
alpha-antagonists ||| S:1841 E:1858 ||| NNP
, ||| S:1858 E:1859 ||| ,
"  ||| S:1859 E:1861 ||| ''
or  ||| S:1861 E:1864 ||| CC
"alpha  ||| S:1864 E:1879 ||| CD
blocker ||| S:1879 E:1886 ||| NN
. ||| S:1886 E:1887 ||| .
"  ||| S:1887 E:1889 ||| ''
The  ||| S:1889 E:1893 ||| DT
search  ||| S:1893 E:1900 ||| NN
was  ||| S:1900 E:1904 ||| VBD
then  ||| S:1904 E:1909 ||| RB
limited  ||| S:1909 E:1917 ||| VBN
to  ||| S:1917 E:1920 ||| TO
clinical  ||| S:1920 E:1929 ||| JJ
trials  ||| S:1929 E:1944 ||| NNS
that  ||| S:1944 E:1949 ||| WDT
had  ||| S:1949 E:1953 ||| VBD
"hypertension ||| S:1953 E:1966 ||| NNP
"  ||| S:1966 E:1968 ||| ''
as  ||| S:1968 E:1971 ||| IN
a  ||| S:1971 E:1973 ||| DT
key  ||| S:1973 E:1977 ||| JJ
word ||| S:1977 E:1981 ||| NN
.  ||| S:1981 E:1983 ||| .
Studies  ||| S:1983 E:1991 ||| NNS
were  ||| S:1991 E:2004 ||| VBD
included  ||| S:2004 E:2013 ||| VBN
in  ||| S:2013 E:2016 ||| IN
our  ||| S:2016 E:2020 ||| PRP$
review  ||| S:2020 E:2027 ||| NN
if  ||| S:2027 E:2030 ||| IN
they  ||| S:2030 E:2035 ||| PRP
addressed  ||| S:2035 E:2045 ||| VBD
either  ||| S:2045 E:2052 ||| RB
one  ||| S:2052 E:2056 ||| CD
or  ||| S:2056 E:2059 ||| CC
a  ||| S:2059 E:2069 ||| DT
combination  ||| S:2069 E:2081 ||| NN
of  ||| S:2081 E:2084 ||| IN
the  ||| S:2084 E:2088 ||| DT
three  ||| S:2088 E:2094 ||| CD
agents  ||| S:2094 E:2101 ||| NNS
as  ||| S:2101 E:2104 ||| IN
the  ||| S:2104 E:2108 ||| DT
main  ||| S:2108 E:2113 ||| JJ
focus  ||| S:2113 E:2119 ||| NN
in  ||| S:2119 E:2122 ||| IN
the  ||| S:2122 E:2134 ||| DT
context  ||| S:2134 E:2142 ||| NN
of  ||| S:2142 E:2145 ||| IN
hypertension  ||| S:2145 E:2158 ||| JJ
therapy  ||| S:2158 E:2166 ||| NN
and  ||| S:2166 E:2170 ||| CC
if  ||| S:2170 E:2173 ||| IN
they  ||| S:2173 E:2178 ||| PRP
in  ||| S:2178 E:2181 ||| IN
some  ||| S:2181 E:2186 ||| DT
way  ||| S:2186 E:2198 ||| NN
addressed  ||| S:2198 E:2208 ||| VBD
the  ||| S:2208 E:2212 ||| DT
outcomes  ||| S:2212 E:2221 ||| NN
of  ||| S:2221 E:2224 ||| IN
interest  ||| S:2224 E:2233 ||| NN
noted  ||| S:2233 E:2239 ||| VBD
above ||| S:2239 E:2244 ||| RB
.  ||| S:2244 E:2246 ||| .
Relevant  ||| S:2246 E:2263 ||| JJ
data  ||| S:2263 E:2268 ||| NNS
from  ||| S:2268 E:2273 ||| IN
these  ||| S:2273 E:2279 ||| DT
studies  ||| S:2279 E:2287 ||| NNS
are  ||| S:2287 E:2291 ||| VBP
reported  ||| S:2291 E:2300 ||| VBN
descriptively ||| S:2300 E:2313 ||| NN
.  ||| S:2313 E:2315 ||| .
Other  ||| S:2315 E:2329 ||| JJ
relevant  ||| S:2329 E:2338 ||| JJ
references  ||| S:2338 E:2349 ||| NNS
were  ||| S:2349 E:2354 ||| VBD
acquired  ||| S:2354 E:2363 ||| VBN
from  ||| S:2363 E:2368 ||| IN
bibliographic  ||| S:2368 E:2390 ||| JJ
searches ||| S:2390 E:2398 ||| NNS
.  ||| S:2398 E:2422 ||| .
Results  ||| S:2422 E:2449 ||| NNS
Use  ||| S:2449 E:2453 ||| NN
in  ||| S:2453 E:2456 ||| IN
Hypertension  ||| S:2456 E:2469 ||| NNP
and  ||| S:2469 E:2473 ||| CC
Prostatism  ||| S:2473 E:2494 ||| NNP
Evidence  ||| S:2494 E:2503 ||| NNP
suggests  ||| S:2503 E:2512 ||| VBZ
that  ||| S:2512 E:2517 ||| IN
alpha-1  ||| S:2517 E:2525 ||| CD
antagonists  ||| S:2525 E:2537 ||| NNS
are  ||| S:2537 E:2551 ||| VBP
frequently  ||| S:2551 E:2562 ||| RB
prescribed  ||| S:2562 E:2573 ||| VBN
for  ||| S:2573 E:2577 ||| IN
hypertension ||| S:2577 E:2589 ||| NN
,  ||| S:2589 E:2591 ||| ,
but  ||| S:2591 E:2595 ||| CC
there  ||| S:2595 E:2601 ||| EX
are  ||| S:2601 E:2605 ||| VBP
few  ||| S:2605 E:2619 ||| JJ
published  ||| S:2619 E:2629 ||| JJ
data  ||| S:2629 E:2634 ||| NNS
concerning  ||| S:2634 E:2645 ||| VBG
the  ||| S:2645 E:2649 ||| DT
prevalence  ||| S:2649 E:2660 ||| NN
of  ||| S:2660 E:2663 ||| IN
the  ||| S:2663 E:2667 ||| DT
routine  ||| S:2667 E:2685 ||| JJ
use  ||| S:2685 E:2689 ||| NN
of  ||| S:2689 E:2692 ||| IN
peripheral  ||| S:2692 E:2703 ||| JJ
alpha-1  ||| S:2703 E:2711 ||| CD
antagonists ||| S:2711 E:2722 ||| NNS
,  ||| S:2722 E:2724 ||| ,
the  ||| S:2724 E:2728 ||| DT
prevalence  ||| S:2728 E:2749 ||| NN
according  ||| S:2749 E:2759 ||| VBG
to  ||| S:2759 E:2762 ||| TO
co-morbid  ||| S:2762 E:2772 ||| JJ
conditions  ||| S:2772 E:2783 ||| NNS
such  ||| S:2783 E:2788 ||| JJ
as  ||| S:2788 E:2791 ||| IN
benign  ||| S:2791 E:2808 ||| JJ
prostatic  ||| S:2808 E:2818 ||| JJ
hypertrophy  ||| S:2818 E:2830 ||| NN
and  ||| S:2830 E:2834 ||| CC
the  ||| S:2834 E:2838 ||| DT
usual  ||| S:2838 E:2844 ||| JJ
duration  ||| S:2844 E:2853 ||| NN
of  ||| S:2853 E:2856 ||| IN
therapy ||| S:2856 E:2863 ||| NN
.  ||| S:2863 E:2875 ||| .
In  ||| S:2875 E:2878 ||| IN
the  ||| S:2878 E:2882 ||| DT
sixth  ||| S:2882 E:2888 ||| JJ
report  ||| S:2888 E:2895 ||| NN
of  ||| S:2895 E:2898 ||| IN
the  ||| S:2898 E:2902 ||| DT
Joint  ||| S:2902 E:2908 ||| NNP
National  ||| S:2908 E:2917 ||| NNP
Committee  ||| S:2917 E:2927 ||| NNP
on  ||| S:2927 E:2940 ||| IN
Prevention ||| S:2940 E:2950 ||| NNP
,  ||| S:2950 E:2952 ||| ,
Detection ||| S:2952 E:2961 ||| NNP
,  ||| S:2961 E:2963 ||| ,
Evaluation ||| S:2963 E:2973 ||| NNP
,  ||| S:2973 E:2975 ||| ,
and  ||| S:2975 E:2979 ||| CC
Treatment  ||| S:2979 E:2989 ||| NNP
of  ||| S:2989 E:2992 ||| IN
High  ||| S:2992 E:3007 ||| NNP
Blood  ||| S:3007 E:3013 ||| NNP
Pressure  ||| S:3013 E:3022 ||| NNP
( ||| S:3022 E:3023 ||| -LRB-
JNC  ||| S:3023 E:3027 ||| NNP
VI ||| S:3027 E:3029 ||| NNP
) ||| S:3029 E:3030 ||| -RRB-
,  ||| S:3030 E:3032 ||| ,
peripheral  ||| S:3032 E:3043 ||| JJ
alpha-1  ||| S:3043 E:3051 ||| CD
antagonists  ||| S:3051 E:3073 ||| NNS
are  ||| S:3073 E:3077 ||| VBP
recommended  ||| S:3077 E:3089 ||| VBN
not  ||| S:3089 E:3093 ||| RB
only  ||| S:3093 E:3098 ||| RB
as  ||| S:3098 E:3101 ||| IN
second-line  ||| S:3101 E:3113 ||| JJ
anti-hypertensive  ||| S:3113 E:3141 ||| JJ
therapy  ||| S:3141 E:3149 ||| NN
after  ||| S:3149 E:3155 ||| IN
low-dose  ||| S:3155 E:3164 ||| JJ
diuretics  ||| S:3164 E:3174 ||| NN
and  ||| S:3174 E:3178 ||| CC
beta  ||| S:3178 E:3183 ||| JJ
blockers ||| S:3183 E:3191 ||| NN
,  ||| S:3191 E:3193 ||| ,
but  ||| S:3193 E:3207 ||| CC
also  ||| S:3207 E:3212 ||| RB
for  ||| S:3212 E:3216 ||| IN
specific  ||| S:3216 E:3225 ||| JJ
indications  ||| S:3225 E:3237 ||| NNS
such  ||| S:3237 E:3242 ||| JJ
as  ||| S:3242 E:3245 ||| IN
therapy  ||| S:3245 E:3253 ||| NN
in  ||| S:3253 E:3256 ||| IN
men  ||| S:3256 E:3260 ||| NNS
with  ||| S:3260 E:3275 ||| IN
hypertension  ||| S:3275 E:3288 ||| NN
and  ||| S:3288 E:3292 ||| CC
prostatism  ||| S:3292 E:3303 ||| NNS
[  ||| S:3303 E:3305 ||| -LRB-
2  ||| S:3305 E:3307 ||| LS
]  ||| S:3307 E:3309 ||| -RRB-
.  ||| S:3309 E:3311 ||| .
Alpha-1  ||| S:3311 E:3319 ||| NNP
antagonists  ||| S:3319 E:3341 ||| NNS
represent  ||| S:3341 E:3351 ||| VBP
effective  ||| S:3351 E:3361 ||| JJ
therapy  ||| S:3361 E:3369 ||| NN
for  ||| S:3369 E:3373 ||| IN
prostatism ||| S:3373 E:3383 ||| NN
,  ||| S:3383 E:3385 ||| ,
and  ||| S:3385 E:3389 ||| CC
fifty  ||| S:3389 E:3405 ||| JJ
percent  ||| S:3405 E:3413 ||| NN
of  ||| S:3413 E:3416 ||| IN
men  ||| S:3416 E:3420 ||| NNS
have  ||| S:3420 E:3425 ||| VBP
histologic  ||| S:3425 E:3436 ||| JJ
evidence  ||| S:3436 E:3445 ||| NN
of  ||| S:3445 E:3448 ||| IN
BPH  ||| S:3448 E:3452 ||| NNP
by  ||| S:3452 E:3455 ||| IN
60  ||| S:3455 E:3468 ||| CD
years  ||| S:3468 E:3474 ||| NNS
of  ||| S:3474 E:3477 ||| IN
age  ||| S:3477 E:3481 ||| NN
[  ||| S:3481 E:3483 ||| -LRB-
3  ||| S:3483 E:3485 ||| CD
4  ||| S:3485 E:3487 ||| CD
]  ||| S:3487 E:3489 ||| -RRB-
.  ||| S:3489 E:3491 ||| .
The  ||| S:3491 E:3495 ||| DT
National  ||| S:3495 E:3504 ||| NNP
Ambulatory  ||| S:3504 E:3515 ||| NNP
Medical  ||| S:3515 E:3533 ||| NNP
Care  ||| S:3533 E:3538 ||| NNP
Survey  ||| S:3538 E:3545 ||| NNP
reported  ||| S:3545 E:3554 ||| VBD
that  ||| S:3554 E:3559 ||| IN
the  ||| S:3559 E:3563 ||| DT
number  ||| S:3563 E:3570 ||| NN
of  ||| S:3570 E:3573 ||| IN
people  ||| S:3573 E:3580 ||| NNS
on  ||| S:3580 E:3583 ||| IN
any  ||| S:3583 E:3597 ||| DT
type  ||| S:3597 E:3602 ||| NN
of  ||| S:3602 E:3605 ||| IN
peripheral  ||| S:3605 E:3616 ||| JJ
alpha-1  ||| S:3616 E:3624 ||| CD
antagonist  ||| S:3624 E:3635 ||| NN
in  ||| S:3635 E:3638 ||| IN
1995  ||| S:3638 E:3643 ||| CD
was  ||| S:3643 E:3657 ||| VBD
approximately  ||| S:3657 E:3671 ||| RB
6  ||| S:3671 E:3673 ||| CD
to  ||| S:3673 E:3676 ||| TO
7 ||| S:3676 E:3677 ||| CD
%  ||| S:3677 E:3679 ||| NN
of  ||| S:3679 E:3682 ||| IN
those  ||| S:3682 E:3688 ||| DT
with  ||| S:3688 E:3693 ||| IN
hypertension  ||| S:3693 E:3706 ||| NN
[  ||| S:3706 E:3708 ||| -LRB-
5  ||| S:3708 E:3710 ||| LS
]  ||| S:3710 E:3712 ||| -RRB-
.  ||| S:3712 E:3724 ||| .
About  ||| S:3724 E:3730 ||| IN
80 ||| S:3730 E:3732 ||| CD
%  ||| S:3732 E:3734 ||| NN
of  ||| S:3734 E:3737 ||| IN
surveyed  ||| S:3737 E:3746 ||| JJ
physicians  ||| S:3746 E:3757 ||| NNS
would  ||| S:3757 E:3763 ||| MD
choose  ||| S:3763 E:3770 ||| VB
these  ||| S:3770 E:3776 ||| DT
drugs  ||| S:3776 E:3792 ||| NNS
as  ||| S:3792 E:3795 ||| IN
a  ||| S:3795 E:3797 ||| DT
first-line  ||| S:3797 E:3808 ||| JJ
blood  ||| S:3808 E:3814 ||| NN
pressure  ||| S:3814 E:3823 ||| NN
agent  ||| S:3823 E:3829 ||| NN
for  ||| S:3829 E:3833 ||| IN
patients  ||| S:3833 E:3842 ||| NNS
with  ||| S:3842 E:3857 ||| IN
hypertension  ||| S:3857 E:3870 ||| NN
and  ||| S:3870 E:3874 ||| CC
symptoms  ||| S:3874 E:3883 ||| NNS
of  ||| S:3883 E:3886 ||| IN
BPH  ||| S:3886 E:3890 ||| NNP
[  ||| S:3890 E:3892 ||| -LRB-
6  ||| S:3892 E:3894 ||| CD
]  ||| S:3894 E:3896 ||| -RRB-
.  ||| S:3896 E:3926 ||| .
Weight  ||| S:3926 E:3933 ||| NN
and  ||| S:3933 E:3937 ||| CC
Fluid  ||| S:3937 E:3943 ||| NNP
Status  ||| S:3943 E:3960 ||| NNP
Peripheral  ||| S:3960 E:3971 ||| NNP
alpha-1  ||| S:3971 E:3979 ||| NNP
antagonists  ||| S:3979 E:3991 ||| NNS
were  ||| S:3991 E:3996 ||| VBD
consistently  ||| S:3996 E:4019 ||| RB
associated  ||| S:4019 E:4030 ||| VBN
with  ||| S:4030 E:4035 ||| IN
fluid  ||| S:4035 E:4041 ||| JJ
retention ||| S:4041 E:4050 ||| NN
.  ||| S:4050 E:4052 ||| .
A  ||| S:4052 E:4054 ||| DT
1984  ||| S:4054 E:4059 ||| CD
study  ||| S:4059 E:4065 ||| NN
of  ||| S:4065 E:4068 ||| IN
prazosin  ||| S:4068 E:4087 ||| NN
reported  ||| S:4087 E:4096 ||| VBD
by  ||| S:4096 E:4099 ||| IN
Bauer  ||| S:4099 E:4105 ||| NNP
revealed  ||| S:4105 E:4114 ||| VBD
increases  ||| S:4114 E:4124 ||| NNS
in  ||| S:4124 E:4127 ||| IN
plasma  ||| S:4127 E:4134 ||| JJ
volume ||| S:4134 E:4140 ||| NN
,  ||| S:4140 E:4152 ||| ,
interstitial  ||| S:4152 E:4165 ||| JJ
fluid  ||| S:4165 E:4171 ||| JJ
volume ||| S:4171 E:4177 ||| NN
,  ||| S:4177 E:4179 ||| ,
and  ||| S:4179 E:4183 ||| CC
extracellular  ||| S:4183 E:4197 ||| JJ
fluid  ||| S:4197 E:4203 ||| JJ
volume  ||| S:4203 E:4220 ||| NN
following  ||| S:4220 E:4230 ||| VBG
both  ||| S:4230 E:4235 ||| DT
short-term  ||| S:4235 E:4246 ||| JJ
and  ||| S:4246 E:4250 ||| CC
long-term  ||| S:4250 E:4260 ||| JJ
therapy  ||| S:4260 E:4268 ||| NN
[  ||| S:4268 E:4270 ||| -LRB-
7  ||| S:4270 E:4272 ||| CD
]  ||| S:4272 E:4274 ||| -RRB-
.  ||| S:4274 E:4286 ||| .
In  ||| S:4286 E:4289 ||| IN
this  ||| S:4289 E:4294 ||| DT
study  ||| S:4294 E:4300 ||| NN
of  ||| S:4300 E:4303 ||| IN
14  ||| S:4303 E:4306 ||| CD
hypertensive  ||| S:4306 E:4319 ||| CD
men ||| S:4319 E:4322 ||| NNS
,  ||| S:4322 E:4324 ||| ,
there  ||| S:4324 E:4330 ||| EX
was  ||| S:4330 E:4334 ||| VBD
a  ||| S:4334 E:4346 ||| DT
significant  ||| S:4346 E:4358 ||| JJ
1.4  ||| S:4358 E:4362 ||| CD
L  ||| S:4362 E:4364 ||| NNP
average  ||| S:4364 E:4372 ||| JJ
increase  ||| S:4372 E:4381 ||| NN
in  ||| S:4381 E:4384 ||| IN
ECFV ||| S:4384 E:4388 ||| NNP
,  ||| S:4388 E:4390 ||| ,
with  ||| S:4390 E:4395 ||| IN
a  ||| S:4395 E:4397 ||| DT
200  ||| S:4397 E:4401 ||| CD
mL  ||| S:4401 E:4414 ||| JJ
average  ||| S:4414 E:4422 ||| JJ
increase  ||| S:4422 E:4431 ||| NN
in  ||| S:4431 E:4434 ||| IN
plasma  ||| S:4434 E:4441 ||| JJ
volume  ||| S:4441 E:4448 ||| NN
( ||| S:4448 E:4449 ||| -LRB-
measured  ||| S:4449 E:4458 ||| VBN
with  ||| S:4458 E:4473 ||| IN
radioisotopic  ||| S:4473 E:4487 ||| JJ
assays ||| S:4487 E:4493 ||| NN
)  ||| S:4493 E:4495 ||| -RRB-
that  ||| S:4495 E:4500 ||| WDT
occurred  ||| S:4500 E:4509 ||| VBD
within  ||| S:4509 E:4516 ||| IN
3-6  ||| S:4516 E:4520 ||| CD
weeks  ||| S:4520 E:4526 ||| NNS
of  ||| S:4526 E:4539 ||| IN
initiation ||| S:4539 E:4549 ||| NN
,  ||| S:4549 E:4551 ||| ,
lasted  ||| S:4551 E:4558 ||| VBD
during  ||| S:4558 E:4565 ||| IN
5  ||| S:4565 E:4567 ||| CD
to  ||| S:4567 E:4570 ||| TO
6  ||| S:4570 E:4572 ||| CD
months  ||| S:4572 E:4579 ||| NNS
of  ||| S:4579 E:4582 ||| IN
chronic  ||| S:4582 E:4600 ||| JJ
therapy ||| S:4600 E:4607 ||| NN
,  ||| S:4607 E:4609 ||| ,
and  ||| S:4609 E:4613 ||| CC
was  ||| S:4613 E:4617 ||| VBD
still  ||| S:4617 E:4623 ||| RB
present  ||| S:4623 E:4631 ||| VB
during  ||| S:4631 E:4638 ||| IN
a  ||| S:4638 E:4640 ||| DT
two-week  ||| S:4640 E:4649 ||| JJ
washout  ||| S:4649 E:4667 ||| JJ
period ||| S:4667 E:4673 ||| NN
.  ||| S:4673 E:4675 ||| .
There  ||| S:4675 E:4681 ||| EX
was  ||| S:4681 E:4685 ||| VBD
no  ||| S:4685 E:4688 ||| DT
weight  ||| S:4688 E:4695 ||| NN
change  ||| S:4695 E:4702 ||| NN
in  ||| S:4702 E:4705 ||| IN
that  ||| S:4705 E:4710 ||| DT
study ||| S:4710 E:4715 ||| NN
,  ||| S:4715 E:4717 ||| ,
but  ||| S:4717 E:4721 ||| CC
two  ||| S:4721 E:4735 ||| CD
other  ||| S:4735 E:4741 ||| JJ
studies  ||| S:4741 E:4749 ||| NNS
demonstrated  ||| S:4749 E:4762 ||| VBD
both  ||| S:4762 E:4767 ||| PDT
an  ||| S:4767 E:4770 ||| DT
increase  ||| S:4770 E:4779 ||| NN
in  ||| S:4779 E:4782 ||| IN
weight  ||| S:4782 E:4789 ||| NN
as  ||| S:4789 E:4802 ||| IN
well  ||| S:4802 E:4807 ||| RB
as  ||| S:4807 E:4810 ||| IN
laboratory  ||| S:4810 E:4821 ||| NN
changes  ||| S:4821 E:4829 ||| NNS
consistent  ||| S:4829 E:4840 ||| JJ
with  ||| S:4840 E:4845 ||| IN
volume  ||| S:4845 E:4862 ||| NN
expansion  ||| S:4862 E:4872 ||| NN
for  ||| S:4872 E:4876 ||| IN
prazosin  ||| S:4876 E:4885 ||| NNS
[  ||| S:4885 E:4887 ||| -LRB-
8  ||| S:4887 E:4889 ||| CD
9  ||| S:4889 E:4891 ||| CD
]  ||| S:4891 E:4893 ||| -RRB-
.  ||| S:4893 E:4895 ||| .
Bauer  ||| S:4895 E:4901 ||| NNP
and  ||| S:4901 E:4905 ||| CC
his  ||| S:4905 E:4909 ||| PRP$
colleagues  ||| S:4909 E:4930 ||| NNS
suggested  ||| S:4930 E:4940 ||| VBD
that  ||| S:4940 E:4945 ||| IN
a  ||| S:4945 E:4947 ||| DT
net  ||| S:4947 E:4951 ||| JJ
increase  ||| S:4951 E:4960 ||| NN
in  ||| S:4960 E:4963 ||| IN
total  ||| S:4963 E:4969 ||| JJ
body  ||| S:4969 E:4974 ||| NN
sodium  ||| S:4974 E:4981 ||| NN
from  ||| S:4981 E:4996 ||| IN
an  ||| S:4996 E:4999 ||| DT
acute  ||| S:4999 E:5005 ||| JJ
renal  ||| S:5005 E:5011 ||| JJ
effect  ||| S:5011 E:5018 ||| NN
of  ||| S:5018 E:5021 ||| IN
prazosin  ||| S:5021 E:5030 ||| NN
was  ||| S:5030 E:5034 ||| VBD
offset  ||| S:5034 E:5041 ||| VBN
by  ||| S:5041 E:5044 ||| IN
a  ||| S:5044 E:5056 ||| DT
decrease  ||| S:5056 E:5065 ||| NN
in  ||| S:5065 E:5068 ||| IN
actual  ||| S:5068 E:5075 ||| JJ
body  ||| S:5075 E:5080 ||| NN
weight ||| S:5080 E:5086 ||| NN
.  ||| S:5086 E:5088 ||| .
They  ||| S:5088 E:5093 ||| PRP
also  ||| S:5093 E:5098 ||| RB
demonstrated  ||| S:5098 E:5121 ||| VBN
that  ||| S:5121 E:5126 ||| IN
the  ||| S:5126 E:5130 ||| DT
fractional  ||| S:5130 E:5141 ||| JJ
excretion  ||| S:5141 E:5151 ||| NN
of  ||| S:5151 E:5154 ||| IN
sodium  ||| S:5154 E:5161 ||| NN
was  ||| S:5161 E:5165 ||| VBD
unchanged  ||| S:5165 E:5185 ||| JJ
during  ||| S:5185 E:5192 ||| IN
treatment ||| S:5192 E:5201 ||| NN
,  ||| S:5201 E:5203 ||| ,
and  ||| S:5203 E:5207 ||| CC
further  ||| S:5207 E:5215 ||| RB
suggested  ||| S:5215 E:5225 ||| VBN
that  ||| S:5225 E:5230 ||| IN
the  ||| S:5230 E:5234 ||| DT
acute  ||| S:5234 E:5250 ||| JJ
changes  ||| S:5250 E:5258 ||| NNS
were  ||| S:5258 E:5263 ||| VBD
followed  ||| S:5263 E:5272 ||| VBN
by  ||| S:5272 E:5275 ||| IN
chronic  ||| S:5275 E:5283 ||| JJ
sodium  ||| S:5283 E:5290 ||| NN
homeostasis  ||| S:5290 E:5302 ||| NNS
and  ||| S:5302 E:5316 ||| CC
maintenance  ||| S:5316 E:5328 ||| NN
of  ||| S:5328 E:5331 ||| IN
the  ||| S:5331 E:5335 ||| DT
increased  ||| S:5335 E:5345 ||| JJ
total  ||| S:5345 E:5351 ||| JJ
body  ||| S:5351 E:5356 ||| NN
sodium ||| S:5356 E:5362 ||| NN
.  ||| S:5362 E:5374 ||| .
The  ||| S:5374 E:5378 ||| DT
VA  ||| S:5378 E:5381 ||| NNP
Cooperative  ||| S:5381 E:5393 ||| NNP
Study  ||| S:5393 E:5399 ||| NNP
on  ||| S:5399 E:5402 ||| IN
Antihypertensive  ||| S:5402 E:5419 ||| NNP
agents  ||| S:5419 E:5436 ||| NNS
was  ||| S:5436 E:5440 ||| VBD
a  ||| S:5440 E:5442 ||| DT
double-blind ||| S:5442 E:5454 ||| JJ
,  ||| S:5454 E:5456 ||| ,
randomized  ||| S:5456 E:5467 ||| VBD
controlled  ||| S:5467 E:5478 ||| VBN
trial  ||| S:5478 E:5484 ||| NN
comparing  ||| S:5484 E:5504 ||| VBG
atenolol ||| S:5504 E:5512 ||| NN
,  ||| S:5512 E:5514 ||| ,
captopril ||| S:5514 E:5523 ||| NN
,  ||| S:5523 E:5525 ||| ,
clonidine ||| S:5525 E:5534 ||| NN
,  ||| S:5534 E:5536 ||| ,
diltiazem ||| S:5536 E:5545 ||| NN
,  ||| S:5545 E:5557 ||| ,
hydrochlorothiazide ||| S:5557 E:5576 ||| NN
,  ||| S:5576 E:5578 ||| ,
prazosin ||| S:5578 E:5586 ||| NN
,  ||| S:5586 E:5588 ||| ,
and  ||| S:5588 E:5592 ||| CC
placebo  ||| S:5592 E:5600 ||| NN
for  ||| S:5600 E:5614 ||| IN
differences  ||| S:5614 E:5626 ||| NNS
in  ||| S:5626 E:5629 ||| IN
antihypertensive  ||| S:5629 E:5646 ||| JJ
efficacy  ||| S:5646 E:5655 ||| NN
in  ||| S:5655 E:5658 ||| IN
1,105  ||| S:5658 E:5664 ||| CD
men  ||| S:5664 E:5668 ||| NNS
who  ||| S:5668 E:5682 ||| WP
had  ||| S:5682 E:5686 ||| VBD
mild  ||| S:5686 E:5691 ||| JJ
diastolic  ||| S:5691 E:5701 ||| JJ
hypertension  ||| S:5701 E:5714 ||| NN
[  ||| S:5714 E:5716 ||| -LRB-
10  ||| S:5716 E:5719 ||| CD
]  ||| S:5719 E:5721 ||| -RRB-
.  ||| S:5721 E:5723 ||| .
A  ||| S:5723 E:5725 ||| DT
highly  ||| S:5725 E:5742 ||| RB
significant  ||| S:5742 E:5754 ||| JJ
weight  ||| S:5754 E:5761 ||| NN
gain  ||| S:5761 E:5766 ||| NN
of  ||| S:5766 E:5769 ||| IN
1  ||| S:5769 E:5771 ||| CD
kilogram  ||| S:5771 E:5780 ||| NNS
was  ||| S:5780 E:5784 ||| VBD
observed  ||| S:5784 E:5793 ||| VBN
at  ||| S:5793 E:5796 ||| IN
8  ||| S:5796 E:5808 ||| CD
weeks  ||| S:5808 E:5814 ||| NNS
with  ||| S:5814 E:5819 ||| IN
prazosin  ||| S:5819 E:5828 ||| VBG
compared  ||| S:5828 E:5837 ||| VBN
to  ||| S:5837 E:5840 ||| TO
baseline  ||| S:5840 E:5849 ||| VB
( ||| S:5849 E:5850 ||| -LRB-
p  ||| S:5850 E:5852 ||| FW
< ||| S:5852 E:5854 ||| SYM
.001 ||| S:5854 E:5858 ||| FW
) ||| S:5858 E:5859 ||| -RRB-
,  ||| S:5859 E:5871 ||| ,
and  ||| S:5871 E:5875 ||| CC
this  ||| S:5875 E:5880 ||| DT
gain  ||| S:5880 E:5885 ||| NN
was  ||| S:5885 E:5889 ||| VBD
also  ||| S:5889 E:5894 ||| RB
statistically  ||| S:5894 E:5908 ||| RB
significant  ||| S:5908 E:5920 ||| JJ
when  ||| S:5920 E:5935 ||| WRB
compared  ||| S:5935 E:5944 ||| VBN
to  ||| S:5944 E:5947 ||| TO
the  ||| S:5947 E:5951 ||| DT
8-week  ||| S:5951 E:5958 ||| JJ
weight  ||| S:5958 E:5965 ||| NN
changes  ||| S:5965 E:5973 ||| NNS
in  ||| S:5973 E:5976 ||| IN
all  ||| S:5976 E:5980 ||| DT
other  ||| S:5980 E:5986 ||| JJ
groups  ||| S:5986 E:6003 ||| NNS
that  ||| S:6003 E:6008 ||| WDT
had  ||| S:6008 E:6012 ||| VBD
experienced  ||| S:6012 E:6024 ||| VBN
either  ||| S:6024 E:6031 ||| DT
weight  ||| S:6031 E:6038 ||| NN
loss  ||| S:6038 E:6043 ||| NN
or  ||| S:6043 E:6046 ||| CC
no  ||| S:6046 E:6049 ||| DT
mean  ||| S:6049 E:6054 ||| JJ
weight  ||| S:6054 E:6071 ||| NN
change  ||| S:6071 E:6078 ||| NN
( ||| S:6078 E:6079 ||| -LRB-
p  ||| S:6079 E:6081 ||| CD
< ||| S:6081 E:6083 ||| SYM
0.05 ||| S:6083 E:6087 ||| CD
) ||| S:6087 E:6088 ||| -RRB-
.  ||| S:6088 E:6090 ||| .
The  ||| S:6090 E:6094 ||| DT
prazosin  ||| S:6094 E:6103 ||| JJ
arm  ||| S:6103 E:6107 ||| NN
had  ||| S:6107 E:6111 ||| VBD
the  ||| S:6111 E:6115 ||| DT
highest  ||| S:6115 E:6133 ||| JJS
rate  ||| S:6133 E:6138 ||| NN
of  ||| S:6138 E:6141 ||| IN
adverse  ||| S:6141 E:6149 ||| JJ
effects ||| S:6149 E:6156 ||| NNS
,  ||| S:6156 E:6158 ||| ,
leading  ||| S:6158 E:6166 ||| VBG
to  ||| S:6166 E:6169 ||| TO
discontinuation  ||| S:6169 E:6185 ||| VB
of  ||| S:6185 E:6198 ||| IN
treatment ||| S:6198 E:6207 ||| NN
.  ||| S:6207 E:6209 ||| .
The  ||| S:6209 E:6213 ||| DT
termination  ||| S:6213 E:6225 ||| NN
rate  ||| S:6225 E:6230 ||| NN
of  ||| S:6230 E:6233 ||| IN
13.8 ||| S:6233 E:6237 ||| CD
%  ||| S:6237 E:6239 ||| NN
was  ||| S:6239 E:6243 ||| VBD
higher  ||| S:6243 E:6250 ||| JJR
than  ||| S:6250 E:6265 ||| IN
the  ||| S:6265 E:6269 ||| DT
termination  ||| S:6269 E:6281 ||| NN
rate  ||| S:6281 E:6286 ||| NN
from  ||| S:6286 E:6291 ||| IN
adverse  ||| S:6291 E:6299 ||| JJ
effects  ||| S:6299 E:6307 ||| NNS
for  ||| S:6307 E:6311 ||| IN
clonidine  ||| S:6311 E:6331 ||| NNS
( ||| S:6331 E:6332 ||| -LRB-
10.1 ||| S:6332 E:6336 ||| CD
% ||| S:6336 E:6337 ||| NN
) ||| S:6337 E:6338 ||| -RRB-
,  ||| S:6338 E:6340 ||| ,
and  ||| S:6340 E:6344 ||| CC
significantly  ||| S:6344 E:6358 ||| RB
higher  ||| S:6358 E:6365 ||| JJR
than  ||| S:6365 E:6370 ||| IN
the  ||| S:6370 E:6374 ||| DT
rates  ||| S:6374 E:6380 ||| NNS
for  ||| S:6380 E:6394 ||| IN
captopril  ||| S:6394 E:6404 ||| NNS
( ||| S:6404 E:6405 ||| -LRB-
4.8 ||| S:6405 E:6408 ||| CD
% ||| S:6408 E:6409 ||| NN
) ||| S:6409 E:6410 ||| -RRB-
,  ||| S:6410 E:6412 ||| ,
atenolol  ||| S:6412 E:6421 ||| NNS
( ||| S:6421 E:6422 ||| -LRB-
2.2 ||| S:6422 E:6425 ||| CD
% ||| S:6425 E:6426 ||| NN
) ||| S:6426 E:6427 ||| -RRB-
,  ||| S:6427 E:6429 ||| ,
or  ||| S:6429 E:6432 ||| CC
hydrochlorothiazide  ||| S:6432 E:6462 ||| NNS
( ||| S:6462 E:6463 ||| -LRB-
1.1 ||| S:6463 E:6466 ||| CD
% ||| S:6466 E:6467 ||| NN
)  ||| S:6467 E:6469 ||| -RRB-
[  ||| S:6469 E:6471 ||| -LRB-
11  ||| S:6471 E:6474 ||| CD
]  ||| S:6474 E:6476 ||| -RRB-
.  ||| S:6476 E:6478 ||| .
The  ||| S:6478 E:6482 ||| DT
number  ||| S:6482 E:6489 ||| NN
of  ||| S:6489 E:6492 ||| IN
men  ||| S:6492 E:6496 ||| NNS
treated  ||| S:6496 E:6504 ||| VBN
with  ||| S:6504 E:6509 ||| IN
prazosin  ||| S:6509 E:6528 ||| JJ
decreased  ||| S:6528 E:6538 ||| NN
from  ||| S:6538 E:6543 ||| IN
62  ||| S:6543 E:6546 ||| CD
at  ||| S:6546 E:6549 ||| IN
the  ||| S:6549 E:6553 ||| DT
beginning  ||| S:6553 E:6563 ||| NN
of  ||| S:6563 E:6566 ||| IN
the  ||| S:6566 E:6570 ||| DT
trial  ||| S:6570 E:6576 ||| NN
to  ||| S:6576 E:6579 ||| TO
28  ||| S:6579 E:6582 ||| CD
by  ||| S:6582 E:6595 ||| IN
the  ||| S:6595 E:6599 ||| DT
end ||| S:6599 E:6602 ||| NN
.  ||| S:6602 E:6604 ||| .
The  ||| S:6604 E:6608 ||| DT
average  ||| S:6608 E:6616 ||| JJ
weight  ||| S:6616 E:6623 ||| NN
gain  ||| S:6623 E:6628 ||| NN
of  ||| S:6628 E:6631 ||| IN
0.5  ||| S:6631 E:6635 ||| CD
kilograms  ||| S:6635 E:6645 ||| NNS
from  ||| S:6645 E:6660 ||| IN
baseline  ||| S:6660 E:6669 ||| NN
was  ||| S:6669 E:6673 ||| VBD
no  ||| S:6673 E:6676 ||| DT
longer  ||| S:6676 E:6683 ||| RBR
statistically  ||| S:6683 E:6697 ||| JJ
significant  ||| S:6697 E:6709 ||| JJ
at  ||| S:6709 E:6712 ||| IN
one  ||| S:6712 E:6726 ||| CD
year  ||| S:6726 E:6731 ||| NN
of  ||| S:6731 E:6734 ||| IN
therapy  ||| S:6734 E:6742 ||| NN
when  ||| S:6742 E:6747 ||| WRB
compared  ||| S:6747 E:6756 ||| VBN
to  ||| S:6756 E:6759 ||| TO
the  ||| S:6759 E:6763 ||| DT
original  ||| S:6763 E:6772 ||| JJ
baseline  ||| S:6772 E:6791 ||| NN
weight  ||| S:6791 E:6798 ||| NN
or  ||| S:6798 E:6801 ||| CC
the  ||| S:6801 E:6805 ||| DT
other  ||| S:6805 E:6811 ||| JJ
therapies ||| S:6811 E:6820 ||| NNS
.  ||| S:6820 E:6832 ||| .
Safety  ||| S:6832 E:6839 ||| NNP
and  ||| S:6839 E:6843 ||| CC
tolerability  ||| S:6843 E:6856 ||| JJ
trials  ||| S:6856 E:6863 ||| NNS
with  ||| S:6863 E:6868 ||| IN
terazosin  ||| S:6868 E:6878 ||| NNS
have  ||| S:6878 E:6893 ||| VBP
shown  ||| S:6893 E:6899 ||| VBN
similar  ||| S:6899 E:6907 ||| JJ
results  ||| S:6907 E:6915 ||| NNS
( ||| S:6915 E:6916 ||| -LRB-
Table  ||| S:6916 E:6922 ||| NNP
1 ||| S:6922 E:6923 ||| CD
) ||| S:6923 E:6924 ||| -RRB-
.  ||| S:6924 E:6926 ||| .
Patients  ||| S:6926 E:6935 ||| NNS
treated  ||| S:6935 E:6943 ||| VBN
with  ||| S:6943 E:6958 ||| IN
terazosin  ||| S:6958 E:6968 ||| NN
tended  ||| S:6968 E:6975 ||| VBD
to  ||| S:6975 E:6978 ||| TO
gain  ||| S:6978 E:6983 ||| VB
about  ||| S:6983 E:6989 ||| IN
1  ||| S:6989 E:6991 ||| CD
kilogram  ||| S:6991 E:7000 ||| NN
from  ||| S:7000 E:7005 ||| IN
baseline  ||| S:7005 E:7024 ||| NN
on  ||| S:7024 E:7027 ||| IN
active  ||| S:7027 E:7034 ||| JJ
therapy  ||| S:7034 E:7042 ||| NN
during  ||| S:7042 E:7049 ||| IN
these  ||| S:7049 E:7055 ||| DT
trials ||| S:7055 E:7061 ||| NNS
,  ||| S:7061 E:7063 ||| ,
and  ||| S:7063 E:7067 ||| CC
those  ||| S:7067 E:7073 ||| DT
on  ||| S:7073 E:7086 ||| IN
placebo  ||| S:7086 E:7094 ||| JJ
therapy  ||| S:7094 E:7102 ||| NN
lost  ||| S:7102 E:7107 ||| VBD
weight ||| S:7107 E:7113 ||| NN
.  ||| S:7113 E:7115 ||| .
Two  ||| S:7115 E:7119 ||| CD
of  ||| S:7119 E:7122 ||| IN
the  ||| S:7122 E:7126 ||| DT
randomized  ||| S:7126 E:7137 ||| JJ
trials  ||| S:7137 E:7154 ||| NNS
included  ||| S:7154 E:7163 ||| VBD
a  ||| S:7163 E:7165 ||| DT
phase  ||| S:7165 E:7171 ||| NN
for  ||| S:7171 E:7175 ||| IN
withdrawal  ||| S:7175 E:7186 ||| NN
from  ||| S:7186 E:7191 ||| IN
active  ||| S:7191 E:7198 ||| JJ
therapy ||| S:7198 E:7205 ||| NN
,  ||| S:7205 E:7207 ||| ,
with  ||| S:7207 E:7222 ||| IN
weight  ||| S:7222 E:7229 ||| NN
information  ||| S:7229 E:7241 ||| NN
reported  ||| S:7241 E:7250 ||| VBD
by  ||| S:7250 E:7253 ||| IN
Ruoff  ||| S:7253 E:7259 ||| NNP
[  ||| S:7259 E:7261 ||| -LRB-
12  ||| S:7261 E:7264 ||| CD
]  ||| S:7264 E:7266 ||| -RRB-
.  ||| S:7266 E:7268 ||| .
Withdrawal  ||| S:7268 E:7289 ||| NN
from  ||| S:7289 E:7294 ||| IN
active  ||| S:7294 E:7301 ||| JJ
therapy  ||| S:7301 E:7309 ||| NN
was  ||| S:7309 E:7313 ||| VBD
associated  ||| S:7313 E:7324 ||| VBN
with  ||| S:7324 E:7329 ||| IN
a  ||| S:7329 E:7331 ||| DT
loss  ||| S:7331 E:7336 ||| NN
of  ||| S:7336 E:7339 ||| IN
1.3  ||| S:7339 E:7353 ||| CD
kilograms ||| S:7353 E:7362 ||| NNS
.  ||| S:7362 E:7374 ||| .
Doxazosin  ||| S:7374 E:7384 ||| NNP
has  ||| S:7384 E:7388 ||| VBZ
also  ||| S:7388 E:7393 ||| RB
been  ||| S:7393 E:7398 ||| VBN
associated  ||| S:7398 E:7409 ||| VBN
with  ||| S:7409 E:7414 ||| IN
volume  ||| S:7414 E:7431 ||| NN
expansion ||| S:7431 E:7440 ||| NN
.  ||| S:7440 E:7442 ||| .
A  ||| S:7442 E:7444 ||| DT
physiology  ||| S:7444 E:7455 ||| JJ
study  ||| S:7455 E:7461 ||| NN
reported  ||| S:7461 E:7470 ||| VBD
by  ||| S:7470 E:7473 ||| IN
Lund-Johansen  ||| S:7473 E:7497 ||| NNP
demonstrated  ||| S:7497 E:7510 ||| VBD
a  ||| S:7510 E:7512 ||| DT
plasma  ||| S:7512 E:7519 ||| JJ
volume  ||| S:7519 E:7526 ||| NN
fluid  ||| S:7526 E:7532 ||| NN
expansion  ||| S:7532 E:7542 ||| NN
of  ||| S:7542 E:7545 ||| IN
about  ||| S:7545 E:7551 ||| IN
10 ||| S:7551 E:7553 ||| CD
%  ||| S:7553 E:7565 ||| NN
when  ||| S:7565 E:7570 ||| WRB
compared  ||| S:7570 E:7579 ||| VBN
to  ||| S:7579 E:7582 ||| TO
baseline  ||| S:7582 E:7591 ||| VB
values  ||| S:7591 E:7598 ||| NNS
[  ||| S:7598 E:7600 ||| -LRB-
13  ||| S:7600 E:7603 ||| CD
]  ||| S:7603 E:7605 ||| -RRB-
.  ||| S:7605 E:7607 ||| .
Larger  ||| S:7607 E:7624 ||| JJR
randomized  ||| S:7624 E:7635 ||| NNS
controlled  ||| S:7635 E:7646 ||| VBN
trials  ||| S:7646 E:7653 ||| NNS
have  ||| S:7653 E:7658 ||| VBP
also  ||| S:7658 E:7663 ||| RB
consistently  ||| S:7663 E:7686 ||| RB
demonstrated  ||| S:7686 E:7699 ||| VBN
that  ||| S:7699 E:7704 ||| IN
patients  ||| S:7704 E:7713 ||| NNS
treated  ||| S:7713 E:7721 ||| VBN
with  ||| S:7721 E:7726 ||| IN
doxazosin  ||| S:7726 E:7736 ||| JJ
gain  ||| S:7736 E:7751 ||| NN
weight ||| S:7751 E:7757 ||| NN
,  ||| S:7757 E:7759 ||| ,
as  ||| S:7759 E:7762 ||| IN
summarized  ||| S:7762 E:7773 ||| NN
in  ||| S:7773 E:7776 ||| IN
Table  ||| S:7776 E:7782 ||| NNP
2 ||| S:7782 E:7783 ||| CD
.  ||| S:7783 E:7785 ||| .
While  ||| S:7785 E:7791 ||| IN
patients  ||| S:7791 E:7800 ||| NNS
treated  ||| S:7800 E:7818 ||| VBN
with  ||| S:7818 E:7823 ||| IN
doxazosin  ||| S:7823 E:7833 ||| NNS
tend  ||| S:7833 E:7838 ||| VBP
to  ||| S:7838 E:7841 ||| TO
gain  ||| S:7841 E:7846 ||| VB
weight ||| S:7846 E:7852 ||| NN
,  ||| S:7852 E:7854 ||| ,
patients  ||| S:7854 E:7863 ||| NNS
on  ||| S:7863 E:7866 ||| IN
placebo  ||| S:7866 E:7884 ||| JJ
therapy  ||| S:7884 E:7892 ||| NN
lost  ||| S:7892 E:7897 ||| VBD
weight ||| S:7897 E:7903 ||| NN
.  ||| S:7903 E:7905 ||| .
The  ||| S:7905 E:7909 ||| DT
Treatment  ||| S:7909 E:7919 ||| NNP
of  ||| S:7919 E:7922 ||| IN
Mild  ||| S:7922 E:7927 ||| NNP
Hypertension  ||| S:7927 E:7950 ||| NNP
Study  ||| S:7950 E:7956 ||| NNP
( ||| S:7956 E:7957 ||| -LRB-
TOMHS ||| S:7957 E:7962 ||| NNP
)  ||| S:7962 E:7964 ||| -RRB-
trial  ||| S:7964 E:7970 ||| NN
is  ||| S:7970 E:7973 ||| VBZ
a  ||| S:7973 E:7975 ||| DT
notable  ||| S:7975 E:7983 ||| JJ
exception  ||| S:7983 E:7993 ||| NN
for  ||| S:7993 E:7997 ||| IN
the  ||| S:7997 E:8001 ||| DT
trend  ||| S:8001 E:8017 ||| NN
towards  ||| S:8017 E:8025 ||| IN
weight  ||| S:8025 E:8032 ||| NN
gain  ||| S:8032 E:8037 ||| NN
[  ||| S:8037 E:8039 ||| -LRB-
14  ||| S:8039 E:8042 ||| CD
]  ||| S:8042 E:8044 ||| -RRB-
.  ||| S:8044 E:8046 ||| .
All  ||| S:8046 E:8050 ||| DT
five  ||| S:8050 E:8055 ||| CD
treatment  ||| S:8055 E:8065 ||| NN
groups  ||| S:8065 E:8082 ||| NNS
and  ||| S:8082 E:8086 ||| CC
the  ||| S:8086 E:8090 ||| DT
placebo  ||| S:8090 E:8098 ||| JJ
group  ||| S:8098 E:8104 ||| NN
received  ||| S:8104 E:8113 ||| VBD
intensive  ||| S:8113 E:8123 ||| JJ
dietary  ||| S:8123 E:8141 ||| JJ
counseling  ||| S:8141 E:8152 ||| NN
aimed  ||| S:8152 E:8158 ||| VBN
at  ||| S:8158 E:8161 ||| IN
weight  ||| S:8161 E:8168 ||| NN
loss ||| S:8168 E:8172 ||| NN
,  ||| S:8172 E:8174 ||| ,
and  ||| S:8174 E:8178 ||| CC
all  ||| S:8178 E:8182 ||| DT
groups  ||| S:8182 E:8189 ||| NNS
lost  ||| S:8189 E:8204 ||| VBD
weight  ||| S:8204 E:8211 ||| NN
without  ||| S:8211 E:8219 ||| IN
significant  ||| S:8219 E:8231 ||| JJ
differences  ||| S:8231 E:8243 ||| NNS
between  ||| S:8243 E:8251 ||| IN
trial  ||| S:8251 E:8267 ||| NN
arms ||| S:8267 E:8271 ||| NNS
.  ||| S:8271 E:8301 ||| .
Neurohormonal  ||| S:8301 E:8315 ||| NNP
and  ||| S:8315 E:8319 ||| CC
Cellular  ||| S:8319 E:8328 ||| NNP
Effects  ||| S:8328 E:8346 ||| NNPS
Physiologic  ||| S:8346 E:8358 ||| NNP
studies  ||| S:8358 E:8366 ||| NNS
with  ||| S:8366 E:8371 ||| IN
small  ||| S:8371 E:8377 ||| JJ
numbers  ||| S:8377 E:8385 ||| NNS
of  ||| S:8385 E:8388 ||| IN
participants  ||| S:8388 E:8411 ||| NNS
are  ||| S:8411 E:8415 ||| VBP
by  ||| S:8415 E:8418 ||| IN
nature  ||| S:8418 E:8425 ||| NN
underpowered  ||| S:8425 E:8438 ||| NN
to  ||| S:8438 E:8441 ||| TO
detect  ||| S:8441 E:8448 ||| VB
meaningful  ||| S:8448 E:8469 ||| JJ
population  ||| S:8469 E:8480 ||| NN
differences ||| S:8480 E:8491 ||| NNS
,  ||| S:8491 E:8493 ||| ,
but  ||| S:8493 E:8497 ||| CC
may  ||| S:8497 E:8501 ||| MD
provide  ||| S:8501 E:8509 ||| VB
a  ||| S:8509 E:8511 ||| DT
starting  ||| S:8511 E:8520 ||| VBG
point  ||| S:8520 E:8536 ||| NN
when  ||| S:8536 E:8541 ||| WRB
such  ||| S:8541 E:8546 ||| JJ
data  ||| S:8546 E:8551 ||| NNS
are  ||| S:8551 E:8555 ||| VBP
not  ||| S:8555 E:8559 ||| RB
available ||| S:8559 E:8568 ||| JJ
.  ||| S:8568 E:8570 ||| .
Peripheral  ||| S:8570 E:8581 ||| JJ
alpha-1  ||| S:8581 E:8599 ||| CD
antagonists  ||| S:8599 E:8611 ||| NNS
were  ||| S:8611 E:8616 ||| VBD
associated  ||| S:8616 E:8627 ||| VBN
with  ||| S:8627 E:8632 ||| IN
perturbations  ||| S:8632 E:8646 ||| NN
in  ||| S:8646 E:8659 ||| IN
neurohormonal  ||| S:8659 E:8673 ||| JJ
levels  ||| S:8673 E:8680 ||| NNS
in  ||| S:8680 E:8683 ||| IN
various  ||| S:8683 E:8691 ||| JJ
studies ||| S:8691 E:8698 ||| NNS
.  ||| S:8698 E:8700 ||| .
In  ||| S:8700 E:8703 ||| IN
particular ||| S:8703 E:8713 ||| JJ
,  ||| S:8713 E:8725 ||| ,
peripheral  ||| S:8725 E:8736 ||| JJ
alpha-1  ||| S:8736 E:8744 ||| CD
antagonists  ||| S:8744 E:8756 ||| NNS
are  ||| S:8756 E:8760 ||| VBP
associated  ||| S:8760 E:8771 ||| VBN
with  ||| S:8771 E:8776 ||| IN
an  ||| S:8776 E:8789 ||| DT
increase  ||| S:8789 E:8798 ||| NN
in  ||| S:8798 E:8801 ||| IN
plasma  ||| S:8801 E:8808 ||| JJ
norepinephrine  ||| S:8808 E:8823 ||| NN
in  ||| S:8823 E:8826 ||| IN
diverse  ||| S:8826 E:8834 ||| JJ
patient  ||| S:8834 E:8852 ||| NN
populations ||| S:8852 E:8863 ||| NNS
,  ||| S:8863 E:8865 ||| ,
as  ||| S:8865 E:8868 ||| IN
summarized  ||| S:8868 E:8879 ||| NN
in  ||| S:8879 E:8882 ||| IN
Table  ||| S:8882 E:8888 ||| NNP
3 ||| S:8888 E:8889 ||| CD
.  ||| S:8889 E:8891 ||| .
This  ||| S:8891 E:8896 ||| DT
table  ||| S:8896 E:8912 ||| NN
reflects  ||| S:8912 E:8921 ||| VBZ
increases  ||| S:8921 E:8931 ||| NNS
in  ||| S:8931 E:8934 ||| IN
norepinephrine  ||| S:8934 E:8949 ||| NN
in  ||| S:8949 E:8952 ||| IN
normotensive  ||| S:8952 E:8975 ||| JJ
patients ||| S:8975 E:8983 ||| NNS
,  ||| S:8983 E:8985 ||| ,
hypertensive  ||| S:8985 E:8998 ||| JJ
patients ||| S:8998 E:9006 ||| NNS
,  ||| S:9006 E:9008 ||| ,
and  ||| S:9008 E:9012 ||| CC
patients  ||| S:9012 E:9021 ||| NNS
with  ||| S:9021 E:9036 ||| IN
chronic  ||| S:9036 E:9044 ||| JJ
congestive  ||| S:9044 E:9055 ||| JJ
heart  ||| S:9055 E:9061 ||| NN
failure  ||| S:9061 E:9069 ||| NN
from  ||| S:9069 E:9074 ||| IN
a  ||| S:9074 E:9076 ||| DT
variety  ||| S:9076 E:9084 ||| NN
of  ||| S:9084 E:9087 ||| IN
these  ||| S:9087 E:9103 ||| DT
small  ||| S:9103 E:9109 ||| JJ
studies ||| S:9109 E:9116 ||| NNS
.  ||| S:9116 E:9128 ||| .
Several  ||| S:9128 E:9136 ||| JJ
lines  ||| S:9136 E:9142 ||| NNS
of  ||| S:9142 E:9145 ||| IN
evidence  ||| S:9145 E:9154 ||| NN
suggest  ||| S:9154 E:9162 ||| VBP
that  ||| S:9162 E:9167 ||| IN
elevated  ||| S:9167 E:9186 ||| JJ
catecholamine  ||| S:9186 E:9200 ||| JJ
levels  ||| S:9200 E:9207 ||| NNS
are  ||| S:9207 E:9211 ||| VBP
cardiotoxic  ||| S:9211 E:9223 ||| NNS
[  ||| S:9223 E:9225 ||| -LRB-
15  ||| S:9225 E:9228 ||| CD
]  ||| S:9228 E:9230 ||| -RRB-
.  ||| S:9230 E:9232 ||| .
Elevated  ||| S:9232 E:9251 ||| JJ
plasma  ||| S:9251 E:9258 ||| JJ
norepinephrine  ||| S:9258 E:9273 ||| JJ
levels  ||| S:9273 E:9280 ||| NNS
are  ||| S:9280 E:9284 ||| VBP
hypothesized  ||| S:9284 E:9297 ||| VBN
to  ||| S:9297 E:9300 ||| TO
cause  ||| S:9300 E:9316 ||| VB
direct  ||| S:9316 E:9323 ||| JJ
myocardial  ||| S:9323 E:9334 ||| JJ
damage  ||| S:9334 E:9341 ||| NN
through  ||| S:9341 E:9349 ||| IN
many  ||| S:9349 E:9354 ||| JJ
mechanisms ||| S:9354 E:9364 ||| NNS
,  ||| S:9364 E:9366 ||| ,
which  ||| S:9366 E:9382 ||| WDT
may  ||| S:9382 E:9386 ||| MD
be  ||| S:9386 E:9389 ||| VB
amplified  ||| S:9389 E:9399 ||| VBN
by  ||| S:9399 E:9402 ||| IN
concomitant  ||| S:9402 E:9414 ||| CD
alpha-1  ||| S:9414 E:9422 ||| CD
blockade ||| S:9422 E:9430 ||| NN
.  ||| S:9430 E:9432 ||| .
In  ||| S:9432 E:9445 ||| IN
rats ||| S:9445 E:9449 ||| NNS
,  ||| S:9449 E:9451 ||| ,
norepinephrine  ||| S:9451 E:9466 ||| FW
stimulates  ||| S:9466 E:9477 ||| FW
apoptosis ||| S:9477 E:9486 ||| FW
,  ||| S:9486 E:9488 ||| ,
which  ||| S:9488 E:9494 ||| WDT
is  ||| S:9494 E:9507 ||| VBZ
mediated  ||| S:9507 E:9516 ||| VBN
through  ||| S:9516 E:9524 ||| IN
beta  ||| S:9524 E:9529 ||| JJ
receptors  ||| S:9529 E:9539 ||| NNS
[  ||| S:9539 E:9541 ||| -LRB-
16  ||| S:9541 E:9544 ||| CD
]  ||| S:9544 E:9546 ||| -RRB-
.  ||| S:9546 E:9548 ||| .
In  ||| S:9548 E:9551 ||| IN
addition ||| S:9551 E:9559 ||| NN
,  ||| S:9559 E:9571 ||| ,
alpha-1  ||| S:9571 E:9579 ||| CD
cardiac  ||| S:9579 E:9587 ||| JJ
receptors  ||| S:9587 E:9597 ||| NNS
inhibit  ||| S:9597 E:9605 ||| VBP
this  ||| S:9605 E:9610 ||| DT
response  ||| S:9610 E:9619 ||| NN
in  ||| S:9619 E:9622 ||| IN
rat  ||| S:9622 E:9636 ||| JJ
myocytes  ||| S:9636 E:9645 ||| NNS
[  ||| S:9645 E:9647 ||| -LRB-
17  ||| S:9647 E:9650 ||| CD
]  ||| S:9650 E:9652 ||| -RRB-
.  ||| S:9652 E:9654 ||| .
The  ||| S:9654 E:9658 ||| DT
increased  ||| S:9658 E:9668 ||| JJ
concentration  ||| S:9668 E:9682 ||| NN
of  ||| S:9682 E:9695 ||| IN
norepinephrine  ||| S:9695 E:9710 ||| NNS
leading  ||| S:9710 E:9718 ||| VBG
to  ||| S:9718 E:9721 ||| TO
cardiac  ||| S:9721 E:9729 ||| VB
beta  ||| S:9729 E:9734 ||| JJ
receptor  ||| S:9734 E:9753 ||| NN
stimulation  ||| S:9753 E:9765 ||| VBZ
combined  ||| S:9765 E:9774 ||| VBN
with  ||| S:9774 E:9779 ||| IN
alpha-1  ||| S:9779 E:9787 ||| CD
receptor  ||| S:9787 E:9796 ||| NN
inhibition  ||| S:9796 E:9807 ||| NNS
may  ||| S:9807 E:9821 ||| MD
lead  ||| S:9821 E:9826 ||| VB
to  ||| S:9826 E:9829 ||| TO
increased  ||| S:9829 E:9839 ||| JJ
apoptosis  ||| S:9839 E:9849 ||| NN
in  ||| S:9849 E:9852 ||| IN
myocytes ||| S:9852 E:9860 ||| NN
.  ||| S:9860 E:9872 ||| .
Other  ||| S:9872 E:9878 ||| JJ
hormones  ||| S:9878 E:9887 ||| NNS
that  ||| S:9887 E:9892 ||| WDT
are  ||| S:9892 E:9896 ||| VBP
associated  ||| S:9896 E:9907 ||| VBN
with  ||| S:9907 E:9912 ||| IN
cardiovascular  ||| S:9912 E:9937 ||| JJ
disease  ||| S:9937 E:9945 ||| NN
are  ||| S:9945 E:9949 ||| VBP
affected  ||| S:9949 E:9958 ||| VBN
by  ||| S:9958 E:9961 ||| IN
peripheral  ||| S:9961 E:9972 ||| JJ
alpha-1  ||| S:9972 E:9980 ||| CD
antagonists ||| S:9980 E:9991 ||| NNS
.  ||| S:9991 E:10003 ||| .
Endothelin-1  ||| S:10003 E:10016 ||| NNP
is  ||| S:10016 E:10019 ||| VBZ
a  ||| S:10019 E:10021 ||| DT
vascular  ||| S:10021 E:10030 ||| JJ
hormone ||| S:10030 E:10037 ||| NN
,  ||| S:10037 E:10039 ||| ,
which  ||| S:10039 E:10045 ||| WDT
may  ||| S:10045 E:10049 ||| MD
play  ||| S:10049 E:10054 ||| VB
a  ||| S:10054 E:10056 ||| DT
role  ||| S:10056 E:10071 ||| NN
in  ||| S:10071 E:10074 ||| IN
the  ||| S:10074 E:10078 ||| DT
generation  ||| S:10078 E:10089 ||| NN
and  ||| S:10089 E:10093 ||| CC
maintenance  ||| S:10093 E:10105 ||| NN
of  ||| S:10105 E:10108 ||| IN
heart  ||| S:10108 E:10114 ||| NN
failure  ||| S:10114 E:10122 ||| NN
[  ||| S:10122 E:10124 ||| -LRB-
18  ||| S:10124 E:10127 ||| CD
]  ||| S:10127 E:10139 ||| -RRB-
.  ||| S:10139 E:10141 ||| .
In  ||| S:10141 E:10144 ||| IN
hypertensive  ||| S:10144 E:10157 ||| JJ
patients ||| S:10157 E:10165 ||| NNS
,  ||| S:10165 E:10167 ||| ,
doxazosin  ||| S:10167 E:10177 ||| NN
lowers  ||| S:10177 E:10184 ||| VBZ
von  ||| S:10184 E:10198 ||| NNP
Willebrand  ||| S:10198 E:10209 ||| NNP
factor  ||| S:10209 E:10216 ||| NN
commensurate  ||| S:10216 E:10229 ||| NN
with  ||| S:10229 E:10234 ||| IN
blood  ||| S:10234 E:10240 ||| NN
pressure ||| S:10240 E:10248 ||| NN
,  ||| S:10248 E:10250 ||| ,
but  ||| S:10250 E:10264 ||| CC
it  ||| S:10264 E:10267 ||| PRP
does  ||| S:10267 E:10272 ||| VBZ
not  ||| S:10272 E:10276 ||| RB
lower  ||| S:10276 E:10282 ||| RBR
high  ||| S:10282 E:10287 ||| JJ
levels  ||| S:10287 E:10294 ||| NNS
of  ||| S:10294 E:10297 ||| IN
endothelin-1  ||| S:10297 E:10310 ||| CD
while  ||| S:10310 E:10326 ||| IN
atenolol  ||| S:10326 E:10335 ||| NN
does  ||| S:10335 E:10340 ||| VBZ
[  ||| S:10340 E:10342 ||| -LRB-
19  ||| S:10342 E:10345 ||| CD
]  ||| S:10345 E:10347 ||| -RRB-
.  ||| S:10347 E:10359 ||| .
Other  ||| S:10359 E:10365 ||| JJ
mechanisms  ||| S:10365 E:10376 ||| NNS
for  ||| S:10376 E:10380 ||| IN
cellular  ||| S:10380 E:10389 ||| JJ
injury  ||| S:10389 E:10396 ||| NNS
have  ||| S:10396 E:10401 ||| VBP
been  ||| S:10401 E:10416 ||| VBN
suggested ||| S:10416 E:10425 ||| VBN
.  ||| S:10425 E:10427 ||| .
Hooper  ||| S:10427 E:10434 ||| RB
proposed  ||| S:10434 E:10443 ||| VBN
that  ||| S:10443 E:10448 ||| IN
peripheral  ||| S:10448 E:10459 ||| JJ
alpha-1  ||| S:10459 E:10477 ||| CD
antagonists  ||| S:10477 E:10489 ||| NNS
alter  ||| S:10489 E:10495 ||| VBP
cellular  ||| S:10495 E:10504 ||| JJ
repair  ||| S:10504 E:10511 ||| NN
mechanisms ||| S:10511 E:10521 ||| NNS
,  ||| S:10521 E:10523 ||| ,
possibly  ||| S:10523 E:10542 ||| RB
causing  ||| S:10542 E:10550 ||| VBG
cardiac  ||| S:10550 E:10558 ||| JJ
damage ||| S:10558 E:10564 ||| NN
.  ||| S:10564 E:10566 ||| .
He  ||| S:10566 E:10569 ||| PRP
noted  ||| S:10569 E:10575 ||| VBD
that  ||| S:10575 E:10580 ||| DT
prazosin  ||| S:10580 E:10589 ||| JJ
blocks  ||| S:10589 E:10606 ||| NNS
heat  ||| S:10606 E:10611 ||| NN
shock  ||| S:10611 E:10617 ||| NN
protein  ||| S:10617 E:10625 ||| NN
expression  ||| S:10625 E:10636 ||| NN
in  ||| S:10636 E:10639 ||| IN
myocardium ||| S:10639 E:10649 ||| NN
,  ||| S:10649 E:10651 ||| ,
and  ||| S:10651 E:10655 ||| CC
it  ||| S:10655 E:10658 ||| PRP
has  ||| S:10658 E:10672 ||| VBZ
been  ||| S:10672 E:10677 ||| VBN
hypothesized  ||| S:10677 E:10690 ||| VBN
that  ||| S:10690 E:10695 ||| IN
this  ||| S:10695 E:10700 ||| DT
may  ||| S:10700 E:10704 ||| MD
leave  ||| S:10704 E:10710 ||| VB
myocardium  ||| S:10710 E:10721 ||| VBN
more  ||| S:10721 E:10736 ||| RBR
vulnerable  ||| S:10736 E:10747 ||| JJ
to  ||| S:10747 E:10750 ||| TO
injury  ||| S:10750 E:10757 ||| VB
[  ||| S:10757 E:10759 ||| -LRB-
20  ||| S:10759 E:10762 ||| CD
]  ||| S:10762 E:10764 ||| -RRB-
.  ||| S:10764 E:10794 ||| .
Epidemiological  ||| S:10794 E:10810 ||| NNP
and  ||| S:10810 E:10814 ||| CC
Clinical  ||| S:10814 E:10823 ||| NNP
Trial  ||| S:10823 E:10829 ||| NNP
Data  ||| S:10829 E:10844 ||| NNP
Between  ||| S:10844 E:10852 ||| IN
1966  ||| S:10852 E:10857 ||| CD
and  ||| S:10857 E:10861 ||| CC
2001 ||| S:10861 E:10865 ||| CD
,  ||| S:10865 E:10867 ||| ,
there  ||| S:10867 E:10873 ||| EX
were  ||| S:10873 E:10878 ||| VBD
188  ||| S:10878 E:10882 ||| CD
published  ||| S:10882 E:10902 ||| VBN
cardiovascular  ||| S:10902 E:10917 ||| JJ
randomized  ||| S:10917 E:10928 ||| NNS
controlled  ||| S:10928 E:10939 ||| VBN
trials  ||| S:10939 E:10946 ||| NNS
related  ||| S:10946 E:10954 ||| VBN
to  ||| S:10954 E:10967 ||| TO
the  ||| S:10967 E:10971 ||| DT
treatment  ||| S:10971 E:10981 ||| NN
of  ||| S:10981 E:10984 ||| IN
hypertension  ||| S:10984 E:10997 ||| NN
with  ||| S:10997 E:11002 ||| IN
the  ||| S:11002 E:11006 ||| DT
use  ||| S:11006 E:11010 ||| NN
of  ||| S:11010 E:11013 ||| IN
peripheral  ||| S:11013 E:11034 ||| JJ
alpha-1  ||| S:11034 E:11042 ||| CD
antagonists ||| S:11042 E:11053 ||| NNS
.  ||| S:11053 E:11055 ||| .
Among  ||| S:11055 E:11061 ||| IN
these ||| S:11061 E:11066 ||| DT
,  ||| S:11066 E:11068 ||| ,
only  ||| S:11068 E:11073 ||| RB
ALLHAT  ||| S:11073 E:11090 ||| NNP
specifically  ||| S:11090 E:11103 ||| RB
assessed  ||| S:11103 E:11112 ||| VBN
differences  ||| S:11112 E:11124 ||| NNS
in  ||| S:11124 E:11127 ||| IN
cardiovascular  ||| S:11127 E:11152 ||| JJ
endpoints  ||| S:11152 E:11162 ||| NNS
resulting  ||| S:11162 E:11172 ||| VBG
from  ||| S:11172 E:11177 ||| IN
control  ||| S:11177 E:11185 ||| NN
of  ||| S:11185 E:11188 ||| IN
hypertension  ||| S:11188 E:11201 ||| NN
with  ||| S:11201 E:11206 ||| IN
a  ||| S:11206 E:11218 ||| DT
peripheral  ||| S:11218 E:11229 ||| JJ
alpha-1  ||| S:11229 E:11237 ||| CD
antagonist ||| S:11237 E:11247 ||| NNS
.  ||| S:11247 E:11249 ||| .
Most  ||| S:11249 E:11254 ||| JJS
of  ||| S:11254 E:11257 ||| IN
these  ||| S:11257 E:11263 ||| DT
trials  ||| S:11263 E:11280 ||| NNS
focused  ||| S:11280 E:11288 ||| VBN
on  ||| S:11288 E:11291 ||| IN
surrogate  ||| S:11291 E:11301 ||| JJ
endpoints  ||| S:11301 E:11311 ||| JJ
such  ||| S:11311 E:11316 ||| JJ
as  ||| S:11316 E:11319 ||| IN
equivalence  ||| S:11319 E:11331 ||| NN
of  ||| S:11331 E:11344 ||| IN
blood-pressure  ||| S:11344 E:11359 ||| JJ
reduction  ||| S:11359 E:11369 ||| NN
and  ||| S:11369 E:11373 ||| CC
effects  ||| S:11373 E:11381 ||| NNS
on  ||| S:11381 E:11384 ||| IN
cholesterol ||| S:11384 E:11395 ||| NN
.  ||| S:11395 E:11407 ||| .
Other  ||| S:11407 E:11413 ||| JJ
studies  ||| S:11413 E:11421 ||| NNS
focused  ||| S:11421 E:11429 ||| VBN
on  ||| S:11429 E:11432 ||| IN
tolerability  ||| S:11432 E:11445 ||| NN
and  ||| S:11445 E:11449 ||| CC
pharmacology ||| S:11449 E:11461 ||| NN
.  ||| S:11461 E:11473 ||| .
There  ||| S:11473 E:11479 ||| EX
are  ||| S:11479 E:11483 ||| VBP
no  ||| S:11483 E:11486 ||| DT
case  ||| S:11486 E:11491 ||| NN
control ||| S:11491 E:11498 ||| NN
,  ||| S:11498 E:11500 ||| ,
cohort ||| S:11500 E:11506 ||| NN
,  ||| S:11506 E:11508 ||| ,
or  ||| S:11508 E:11511 ||| CC
other  ||| S:11511 E:11517 ||| JJ
studies  ||| S:11517 E:11525 ||| NNS
that  ||| S:11525 E:11540 ||| WDT
analyzed  ||| S:11540 E:11549 ||| VBD
the  ||| S:11549 E:11553 ||| DT
impact  ||| S:11553 E:11560 ||| NN
of  ||| S:11560 E:11563 ||| IN
these  ||| S:11563 E:11569 ||| DT
agents  ||| S:11569 E:11576 ||| NNS
on  ||| S:11576 E:11579 ||| IN
cardiovascular  ||| S:11579 E:11604 ||| JJ
endpoints ||| S:11604 E:11613 ||| NN
.  ||| S:11613 E:11615 ||| .
Using  ||| S:11615 E:11621 ||| VBG
data  ||| S:11621 E:11626 ||| NNS
from  ||| S:11626 E:11631 ||| IN
other  ||| S:11631 E:11637 ||| JJ
trials  ||| S:11637 E:11644 ||| NNS
may  ||| S:11644 E:11648 ||| MD
offer  ||| S:11648 E:11654 ||| VB
a  ||| S:11654 E:11666 ||| DT
partial  ||| S:11666 E:11674 ||| JJ
framework  ||| S:11674 E:11684 ||| NN
for  ||| S:11684 E:11688 ||| IN
the  ||| S:11688 E:11692 ||| DT
interpretation  ||| S:11692 E:11707 ||| NN
of  ||| S:11707 E:11710 ||| IN
newer  ||| S:11710 E:11726 ||| JJR
findings ||| S:11726 E:11734 ||| NNS
.  ||| S:11734 E:11746 ||| .
ALLHAT  ||| S:11746 E:11753 ||| NNP
demonstrated  ||| S:11753 E:11766 ||| VBD
a  ||| S:11766 E:11768 ||| DT
highly  ||| S:11768 E:11775 ||| RB
statistically  ||| S:11775 E:11799 ||| RB
significant ||| S:11799 E:11810 ||| JJ
,  ||| S:11810 E:11812 ||| ,
near  ||| S:11812 E:11817 ||| IN
doubling  ||| S:11817 E:11826 ||| VBG
in  ||| S:11826 E:11829 ||| IN
the  ||| S:11829 E:11833 ||| DT
incidence  ||| S:11833 E:11843 ||| NN
of  ||| S:11843 E:11846 ||| IN
heart  ||| S:11846 E:11862 ||| NN
failure  ||| S:11862 E:11870 ||| NN
in  ||| S:11870 E:11873 ||| IN
the  ||| S:11873 E:11877 ||| DT
doxazosin  ||| S:11877 E:11887 ||| JJ
arm  ||| S:11887 E:11891 ||| NN
compared  ||| S:11891 E:11900 ||| VBN
to  ||| S:11900 E:11903 ||| TO
heart  ||| S:11903 E:11909 ||| NN
failure  ||| S:11909 E:11927 ||| NN
occurrences  ||| S:11927 E:11939 ||| NNS
in  ||| S:11939 E:11942 ||| IN
the  ||| S:11942 E:11946 ||| DT
chlorthalidone  ||| S:11946 E:11961 ||| JJ
arm ||| S:11961 E:11964 ||| NN
.  ||| S:11964 E:11966 ||| .
Although  ||| S:11966 E:11975 ||| IN
there  ||| S:11975 E:11981 ||| EX
was  ||| S:11981 E:11995 ||| VBD
no  ||| S:11995 E:11998 ||| DT
difference  ||| S:11998 E:12009 ||| NN
in  ||| S:12009 E:12012 ||| IN
the  ||| S:12012 E:12016 ||| DT
primary  ||| S:12016 E:12024 ||| JJ
outcome  ||| S:12024 E:12032 ||| NN
of  ||| S:12032 E:12035 ||| IN
CHD  ||| S:12035 E:12039 ||| NNP
or  ||| S:12039 E:12042 ||| CC
the  ||| S:12042 E:12056 ||| DT
secondary  ||| S:12056 E:12066 ||| JJ
outcome  ||| S:12066 E:12074 ||| NN
of  ||| S:12074 E:12077 ||| IN
total  ||| S:12077 E:12083 ||| JJ
mortality ||| S:12083 E:12092 ||| NN
,  ||| S:12092 E:12094 ||| ,
there  ||| S:12094 E:12100 ||| EX
were  ||| S:12100 E:12105 ||| VBD
small  ||| S:12105 E:12121 ||| JJ
but  ||| S:12121 E:12125 ||| CC
statistically  ||| S:12125 E:12139 ||| RB
significant  ||| S:12139 E:12151 ||| JJ
increases  ||| S:12151 E:12161 ||| NNS
in  ||| S:12161 E:12164 ||| IN
the  ||| S:12164 E:12168 ||| DT
secondary  ||| S:12168 E:12188 ||| JJ
outcomes  ||| S:12188 E:12197 ||| NNS
of  ||| S:12197 E:12200 ||| IN
angina  ||| S:12200 E:12207 ||| NNS
( ||| S:12207 E:12208 ||| -LRB-
RR  ||| S:12208 E:12211 ||| NNP
1.16 ||| S:12211 E:12215 ||| CD
,  ||| S:12215 E:12217 ||| ,
95 ||| S:12217 E:12219 ||| CD
%  ||| S:12219 E:12221 ||| NN
CI  ||| S:12221 E:12224 ||| NNP
1.05-1.27 ||| S:12224 E:12233 ||| NNP
)  ||| S:12233 E:12235 ||| -RRB-
and  ||| S:12235 E:12239 ||| CC
stroke  ||| S:12239 E:12256 ||| NN
( ||| S:12256 E:12257 ||| -LRB-
RR  ||| S:12257 E:12260 ||| NNP
1.19 ||| S:12260 E:12264 ||| CD
,  ||| S:12264 E:12266 ||| ,
95 ||| S:12266 E:12268 ||| CD
%  ||| S:12268 E:12270 ||| NN
CI  ||| S:12270 E:12273 ||| NNP
1.01-1.40 ||| S:12273 E:12282 ||| NNP
) ||| S:12282 E:12283 ||| -RRB-
.  ||| S:12283 E:12285 ||| .
Since  ||| S:12285 E:12291 ||| IN
ALLHAT  ||| S:12291 E:12298 ||| NNP
is  ||| S:12298 E:12301 ||| VBZ
a  ||| S:12301 E:12313 ||| DT
comparative  ||| S:12313 E:12325 ||| JJ
trial ||| S:12325 E:12330 ||| NN
,  ||| S:12330 E:12332 ||| ,
we  ||| S:12332 E:12335 ||| PRP
know  ||| S:12335 E:12340 ||| VBP
that  ||| S:12340 E:12345 ||| DT
doxazosin  ||| S:12345 E:12355 ||| NN
is  ||| S:12355 E:12358 ||| VBZ
associated  ||| S:12358 E:12379 ||| VBN
with  ||| S:12379 E:12384 ||| IN
more  ||| S:12384 E:12389 ||| RBR
adverse  ||| S:12389 E:12397 ||| JJ
cardiovascular  ||| S:12397 E:12412 ||| JJ
outcomes  ||| S:12412 E:12421 ||| NNS
than  ||| S:12421 E:12426 ||| IN
low-dose  ||| S:12426 E:12445 ||| JJ
chlorthalidone ||| S:12445 E:12459 ||| NN
,  ||| S:12459 E:12461 ||| ,
but  ||| S:12461 E:12465 ||| CC
we  ||| S:12465 E:12468 ||| PRP
do  ||| S:12468 E:12471 ||| VBP
not  ||| S:12471 E:12475 ||| RB
know  ||| S:12475 E:12480 ||| VB
how  ||| S:12480 E:12484 ||| WRB
doxazosin  ||| S:12484 E:12494 ||| NNS
might  ||| S:12494 E:12510 ||| MD
compare  ||| S:12510 E:12518 ||| VB
with  ||| S:12518 E:12523 ||| IN
placebo ||| S:12523 E:12530 ||| NN
.  ||| S:12530 E:12532 ||| .
The  ||| S:12532 E:12536 ||| DT
SHEP  ||| S:12536 E:12541 ||| NNP
trial ||| S:12541 E:12546 ||| NN
,  ||| S:12546 E:12548 ||| ,
however ||| S:12548 E:12555 ||| RB
,  ||| S:12555 E:12557 ||| ,
does  ||| S:12557 E:12572 ||| VBZ
provide  ||| S:12572 E:12580 ||| VB
a  ||| S:12580 E:12582 ||| DT
comparison  ||| S:12582 E:12593 ||| NN
between  ||| S:12593 E:12601 ||| IN
chlorthalidone  ||| S:12601 E:12616 ||| NN
and  ||| S:12616 E:12620 ||| CC
placebo  ||| S:12620 E:12638 ||| JJ
therapy  ||| S:12638 E:12646 ||| NN
for  ||| S:12646 E:12650 ||| IN
a  ||| S:12650 E:12652 ||| DT
reference  ||| S:12652 E:12662 ||| NN
point  ||| S:12662 E:12668 ||| NN
of  ||| S:12668 E:12671 ||| IN
heart  ||| S:12671 E:12677 ||| NN
failure ||| S:12677 E:12684 ||| NN
,  ||| S:12684 E:12686 ||| ,
although  ||| S:12686 E:12705 ||| IN
the  ||| S:12705 E:12709 ||| DT
study  ||| S:12709 E:12715 ||| NN
populations  ||| S:12715 E:12727 ||| NNS
have  ||| S:12727 E:12732 ||| VBP
different  ||| S:12732 E:12742 ||| JJ
demographic  ||| S:12742 E:12754 ||| NN
and  ||| S:12754 E:12768 ||| CC
blood  ||| S:12768 E:12774 ||| NN
pressure  ||| S:12774 E:12783 ||| NN
distributions  ||| S:12783 E:12797 ||| NNS
[  ||| S:12797 E:12799 ||| -LRB-
21  ||| S:12799 E:12802 ||| CD
]  ||| S:12802 E:12804 ||| -RRB-
.  ||| S:12804 E:12806 ||| .
The  ||| S:12806 E:12810 ||| DT
SHEP  ||| S:12810 E:12815 ||| NNP
trial  ||| S:12815 E:12831 ||| NN
included  ||| S:12831 E:12840 ||| VBD
4,736  ||| S:12840 E:12846 ||| CD
people  ||| S:12846 E:12853 ||| NNS
aged  ||| S:12853 E:12858 ||| VBN
60  ||| S:12858 E:12861 ||| CD
and  ||| S:12861 E:12865 ||| CC
older  ||| S:12865 E:12871 ||| NNS
who  ||| S:12871 E:12875 ||| WP
had  ||| S:12875 E:12879 ||| VBD
a  ||| S:12879 E:12891 ||| DT
systolic  ||| S:12891 E:12900 ||| JJ
blood  ||| S:12900 E:12906 ||| NN
pressure  ||| S:12906 E:12915 ||| NN
of  ||| S:12915 E:12918 ||| IN
160  ||| S:12918 E:12922 ||| CD
to  ||| S:12922 E:12925 ||| TO
219  ||| S:12925 E:12929 ||| CD
mmHg  ||| S:12929 E:12934 ||| JJ
and  ||| S:12934 E:12938 ||| CC
a  ||| S:12938 E:12950 ||| DT
diastolic  ||| S:12950 E:12960 ||| JJ
blood  ||| S:12960 E:12966 ||| NN
pressure  ||| S:12966 E:12975 ||| NN
of  ||| S:12975 E:12978 ||| IN
less  ||| S:12978 E:12983 ||| JJR
than  ||| S:12983 E:12988 ||| IN
90  ||| S:12988 E:12991 ||| CD
mmHg ||| S:12991 E:12995 ||| NN
.  ||| S:12995 E:12997 ||| .
Subjects  ||| S:12997 E:13016 ||| NNS
were  ||| S:13016 E:13021 ||| VBD
randomized  ||| S:13021 E:13032 ||| VBN
to  ||| S:13032 E:13035 ||| TO
low-dose  ||| S:13035 E:13044 ||| JJ
diuretics  ||| S:13044 E:13054 ||| NN
or  ||| S:13054 E:13057 ||| CC
placebo ||| S:13057 E:13064 ||| NN
,  ||| S:13064 E:13066 ||| ,
and  ||| S:13066 E:13080 ||| CC
were  ||| S:13080 E:13085 ||| VBD
followed  ||| S:13085 E:13094 ||| VBN
for  ||| S:13094 E:13098 ||| IN
an  ||| S:13098 E:13101 ||| DT
average  ||| S:13101 E:13109 ||| NN
of  ||| S:13109 E:13112 ||| IN
4.5  ||| S:13112 E:13116 ||| CD
years  ||| S:13116 E:13122 ||| NNS
for  ||| S:13122 E:13126 ||| IN
major  ||| S:13126 E:13132 ||| JJ
CV  ||| S:13132 E:13145 ||| NN
events ||| S:13145 E:13151 ||| NNS
.  ||| S:13151 E:13153 ||| .
Comparisons  ||| S:13153 E:13165 ||| NNS
between  ||| S:13165 E:13173 ||| IN
those  ||| S:13173 E:13179 ||| DT
randomized  ||| S:13179 E:13190 ||| NN
to  ||| S:13190 E:13193 ||| TO
active  ||| S:13193 E:13210 ||| JJ
therapy  ||| S:13210 E:13218 ||| NN
and  ||| S:13218 E:13222 ||| CC
those  ||| S:13222 E:13228 ||| DT
on  ||| S:13228 E:13231 ||| IN
placebo  ||| S:13231 E:13239 ||| NN
demonstrated  ||| S:13239 E:13252 ||| VBD
nearly  ||| S:13252 E:13259 ||| RB
a  ||| S:13259 E:13261 ||| DT
50 ||| S:13261 E:13263 ||| CD
%  ||| S:13263 E:13275 ||| NN
reduction  ||| S:13275 E:13285 ||| NN
in  ||| S:13285 E:13288 ||| IN
fatal  ||| S:13288 E:13294 ||| JJ
and  ||| S:13294 E:13298 ||| CC
nonfatal  ||| S:13298 E:13307 ||| JJ
heart  ||| S:13307 E:13313 ||| NN
failure  ||| S:13313 E:13321 ||| NN
events  ||| S:13321 E:13328 ||| NNS
( ||| S:13328 E:13329 ||| -LRB-
RR  ||| S:13329 E:13342 ||| NNP
0.51 ||| S:13342 E:13346 ||| NNP
,  ||| S:13346 E:13348 ||| ,
95 ||| S:13348 E:13350 ||| CD
%  ||| S:13350 E:13352 ||| NN
CI  ||| S:13352 E:13355 ||| NNP
0.37-0.71 ||| S:13355 E:13364 ||| NNP
) ||| S:13364 E:13365 ||| -RRB-
.  ||| S:13365 E:13367 ||| .
The  ||| S:13367 E:13371 ||| DT
rates  ||| S:13371 E:13377 ||| NNS
of  ||| S:13377 E:13380 ||| IN
CHF  ||| S:13380 E:13384 ||| NNP
in  ||| S:13384 E:13387 ||| IN
SHEP  ||| S:13387 E:13402 ||| NNP
participants  ||| S:13402 E:13415 ||| NNS
treated  ||| S:13415 E:13423 ||| VBN
with  ||| S:13423 E:13428 ||| IN
diuretics  ||| S:13428 E:13438 ||| NN
and  ||| S:13438 E:13442 ||| CC
placebo  ||| S:13442 E:13450 ||| NN
were  ||| S:13450 E:13455 ||| VBD
5  ||| S:13455 E:13467 ||| CD
and  ||| S:13467 E:13471 ||| CC
10  ||| S:13471 E:13474 ||| CD
per  ||| S:13474 E:13478 ||| IN
1,000  ||| S:13478 E:13484 ||| CD
person-years ||| S:13484 E:13496 ||| NN
,  ||| S:13496 E:13498 ||| ,
respectively ||| S:13498 E:13510 ||| RB
.  ||| S:13510 E:13512 ||| .
In  ||| S:13512 E:13525 ||| IN
comparison ||| S:13525 E:13535 ||| NN
,  ||| S:13535 E:13537 ||| ,
the  ||| S:13537 E:13541 ||| DT
rates  ||| S:13541 E:13547 ||| NNS
of  ||| S:13547 E:13550 ||| IN
CHF  ||| S:13550 E:13554 ||| NNP
in  ||| S:13554 E:13557 ||| IN
ALLHAT  ||| S:13557 E:13564 ||| NNP
participants  ||| S:13564 E:13587 ||| NNS
treated  ||| S:13587 E:13595 ||| VBN
with  ||| S:13595 E:13600 ||| IN
diuretics  ||| S:13600 E:13610 ||| NN
and  ||| S:13610 E:13614 ||| CC
doxazosin  ||| S:13614 E:13624 ||| NNS
were  ||| S:13624 E:13629 ||| VBD
10  ||| S:13629 E:13632 ||| CD
and  ||| S:13632 E:13636 ||| CC
20  ||| S:13636 E:13639 ||| CD
per  ||| S:13639 E:13653 ||| IN
1,000  ||| S:13653 E:13659 ||| CD
person-years ||| S:13659 E:13671 ||| NN
,  ||| S:13671 E:13673 ||| ,
respectively ||| S:13673 E:13685 ||| RB
.  ||| S:13685 E:13687 ||| .
If  ||| S:13687 E:13690 ||| IN
low-dose  ||| S:13690 E:13709 ||| JJ
chlorthalidone  ||| S:13709 E:13724 ||| NN
has  ||| S:13724 E:13728 ||| VBZ
a  ||| S:13728 E:13730 ||| DT
similar  ||| S:13730 E:13738 ||| JJ
risk  ||| S:13738 E:13743 ||| NN
reduction  ||| S:13743 E:13753 ||| NN
in  ||| S:13753 E:13756 ||| IN
the  ||| S:13756 E:13760 ||| DT
ALLHAT  ||| S:13760 E:13777 ||| NNP
population ||| S:13777 E:13787 ||| NN
,  ||| S:13787 E:13789 ||| ,
and  ||| S:13789 E:13793 ||| CC
halves  ||| S:13793 E:13800 ||| VBZ
the  ||| S:13800 E:13804 ||| DT
incidence  ||| S:13804 E:13814 ||| NN
of  ||| S:13814 E:13817 ||| IN
clinical  ||| S:13817 E:13826 ||| JJ
heart  ||| S:13826 E:13842 ||| NN
failure  ||| S:13842 E:13850 ||| NN
events  ||| S:13850 E:13857 ||| NNS
compared  ||| S:13857 E:13866 ||| VBN
to  ||| S:13866 E:13869 ||| TO
no  ||| S:13869 E:13872 ||| DT
therapy ||| S:13872 E:13879 ||| NN
,  ||| S:13879 E:13881 ||| ,
the  ||| S:13881 E:13885 ||| DT
effect  ||| S:13885 E:13892 ||| NN
of  ||| S:13892 E:13905 ||| IN
doxazosin  ||| S:13905 E:13915 ||| NNS
would  ||| S:13915 E:13921 ||| MD
be  ||| S:13921 E:13924 ||| VB
comparable  ||| S:13924 E:13935 ||| JJ
to  ||| S:13935 E:13938 ||| TO
that  ||| S:13938 E:13943 ||| DT
of  ||| S:13943 E:13946 ||| IN
the  ||| S:13946 E:13950 ||| DT
placebo  ||| S:13950 E:13958 ||| JJ
arm  ||| S:13958 E:13972 ||| NN
in  ||| S:13972 E:13975 ||| IN
the  ||| S:13975 E:13979 ||| DT
SHEP  ||| S:13979 E:13984 ||| NNP
trial ||| S:13984 E:13989 ||| NN
.  ||| S:13989 E:14022 ||| .
Conclusions  ||| S:14022 E:14042 ||| NNS
The  ||| S:14042 E:14046 ||| DT
report  ||| S:14046 E:14053 ||| NN
of  ||| S:14053 E:14056 ||| IN
the  ||| S:14056 E:14060 ||| DT
doxazosin  ||| S:14060 E:14070 ||| JJ
arm  ||| S:14070 E:14074 ||| NN
termination  ||| S:14074 E:14086 ||| NN
in  ||| S:14086 E:14089 ||| IN
ALLHAT  ||| S:14089 E:14104 ||| NNP
was  ||| S:14104 E:14108 ||| VBD
published  ||| S:14108 E:14118 ||| VBN
in  ||| S:14118 E:14121 ||| IN
April ||| S:14121 E:14126 ||| NNP
,  ||| S:14126 E:14128 ||| ,
2000 ||| S:14128 E:14132 ||| CD
.  ||| S:14132 E:14134 ||| .
At  ||| S:14134 E:14137 ||| IN
that  ||| S:14137 E:14142 ||| DT
time ||| S:14142 E:14146 ||| NN
,  ||| S:14146 E:14148 ||| ,
the  ||| S:14148 E:14152 ||| DT
results  ||| S:14152 E:14160 ||| NNS
of  ||| S:14160 E:14171 ||| IN
the  ||| S:14171 E:14175 ||| DT
ALLHAT  ||| S:14175 E:14182 ||| NNP
trial  ||| S:14182 E:14188 ||| NN
were  ||| S:14188 E:14193 ||| VBD
unexpected ||| S:14193 E:14203 ||| JJ
,  ||| S:14203 E:14205 ||| ,
given  ||| S:14205 E:14211 ||| VBN
the  ||| S:14211 E:14215 ||| DT
potential  ||| S:14215 E:14233 ||| JJ
association  ||| S:14233 E:14245 ||| NN
between  ||| S:14245 E:14253 ||| IN
high  ||| S:14253 E:14258 ||| JJ
dose  ||| S:14258 E:14263 ||| NN
diuretics  ||| S:14263 E:14273 ||| NNS
and  ||| S:14273 E:14277 ||| CC
the  ||| S:14277 E:14281 ||| DT
risk  ||| S:14281 E:14286 ||| NN
of  ||| S:14286 E:14297 ||| IN
sudden  ||| S:14297 E:14304 ||| JJ
death  ||| S:14304 E:14310 ||| NN
[  ||| S:14310 E:14312 ||| -LRB-
22  ||| S:14312 E:14315 ||| CD
]  ||| S:14315 E:14317 ||| -RRB-
,  ||| S:14317 E:14319 ||| ,
and  ||| S:14319 E:14323 ||| CC
the  ||| S:14323 E:14327 ||| DT
favorable  ||| S:14327 E:14337 ||| JJ
effect  ||| S:14337 E:14344 ||| NN
of  ||| S:14344 E:14355 ||| IN
peripheral  ||| S:14355 E:14366 ||| JJ
alpha-1  ||| S:14366 E:14374 ||| CD
antagonists  ||| S:14374 E:14386 ||| NNS
on  ||| S:14386 E:14389 ||| IN
lipid  ||| S:14389 E:14395 ||| JJ
profiles  ||| S:14395 E:14404 ||| NNS
[  ||| S:14404 E:14406 ||| -LRB-
14  ||| S:14406 E:14409 ||| CD
]  ||| S:14409 E:14411 ||| -RRB-
.  ||| S:14411 E:14421 ||| .
Comparing  ||| S:14421 E:14431 ||| VBG
data  ||| S:14431 E:14436 ||| NNS
from  ||| S:14436 E:14441 ||| IN
other  ||| S:14441 E:14447 ||| JJ
studies  ||| S:14447 E:14455 ||| NNS
suggests  ||| S:14455 E:14464 ||| VBZ
the  ||| S:14464 E:14468 ||| DT
possibility  ||| S:14468 E:14488 ||| NN
that  ||| S:14488 E:14493 ||| IN
the  ||| S:14493 E:14497 ||| DT
beneficial  ||| S:14497 E:14508 ||| JJ
effects  ||| S:14508 E:14516 ||| NNS
of  ||| S:14516 E:14519 ||| IN
peripheral  ||| S:14519 E:14530 ||| JJ
alpha-1  ||| S:14530 E:14546 ||| CD
antagonists  ||| S:14546 E:14558 ||| NNS
for  ||| S:14558 E:14562 ||| IN
lowering  ||| S:14562 E:14571 ||| VBG
blood  ||| S:14571 E:14577 ||| NN
pressure  ||| S:14577 E:14586 ||| NN
may  ||| S:14586 E:14590 ||| MD
be  ||| S:14590 E:14593 ||| VB
nullified  ||| S:14593 E:14603 ||| VBN
by  ||| S:14603 E:14614 ||| IN
a  ||| S:14614 E:14616 ||| DT
negative  ||| S:14616 E:14625 ||| JJ
effect ||| S:14625 E:14631 ||| NN
,  ||| S:14631 E:14633 ||| ,
or  ||| S:14633 E:14636 ||| CC
that  ||| S:14636 E:14641 ||| DT
other  ||| S:14641 E:14647 ||| JJ
antihypertensives  ||| S:14647 E:14665 ||| NNS
have  ||| S:14665 E:14678 ||| VBP
positive  ||| S:14678 E:14687 ||| JJ
actions  ||| S:14687 E:14695 ||| NNS
beyond  ||| S:14695 E:14702 ||| IN
their  ||| S:14702 E:14708 ||| PRP$
antihypertensive  ||| S:14708 E:14725 ||| JJ
effects ||| S:14725 E:14732 ||| NNS
.  ||| S:14732 E:14742 ||| .
Those  ||| S:14742 E:14748 ||| DT
treated  ||| S:14748 E:14756 ||| VBN
with  ||| S:14756 E:14761 ||| IN
doxazosin  ||| S:14761 E:14771 ||| NN
in  ||| S:14771 E:14774 ||| IN
ALLHAT  ||| S:14774 E:14781 ||| NNP
had  ||| S:14781 E:14785 ||| VBD
a  ||| S:14785 E:14787 ||| DT
mean  ||| S:14787 E:14792 ||| JJ
blood  ||| S:14792 E:14806 ||| NN
pressure  ||| S:14806 E:14815 ||| NN
that  ||| S:14815 E:14820 ||| WDT
was  ||| S:14820 E:14824 ||| VBD
2  ||| S:14824 E:14826 ||| CD
to  ||| S:14826 E:14829 ||| TO
3  ||| S:14829 E:14831 ||| CD
mmHg  ||| S:14831 E:14836 ||| JJ
higher  ||| S:14836 E:14843 ||| JJR
than  ||| S:14843 E:14848 ||| IN
the  ||| S:14848 E:14852 ||| DT
mean  ||| S:14852 E:14857 ||| JJ
blood  ||| S:14857 E:14871 ||| NN
pressure  ||| S:14871 E:14880 ||| NN
of  ||| S:14880 E:14883 ||| IN
those  ||| S:14883 E:14889 ||| DT
treated  ||| S:14889 E:14897 ||| VBN
with  ||| S:14897 E:14902 ||| IN
chlorthalidone ||| S:14902 E:14916 ||| NN
.  ||| S:14916 E:14918 ||| .
Based  ||| S:14918 E:14924 ||| VBN
on  ||| S:14924 E:14935 ||| IN
Framingham  ||| S:14935 E:14946 ||| NNP
Heart  ||| S:14946 E:14952 ||| NNP
Study  ||| S:14952 E:14958 ||| NNP
logistic  ||| S:14958 E:14967 ||| FW
regression  ||| S:14967 E:14978 ||| FW
coefficients ||| S:14978 E:14990 ||| FW
,  ||| S:14990 E:15000 ||| ,
this  ||| S:15000 E:15005 ||| DT
2  ||| S:15005 E:15007 ||| CD
to  ||| S:15007 E:15010 ||| TO
3  ||| S:15010 E:15012 ||| CD
mmHg  ||| S:15012 E:15017 ||| JJ
difference  ||| S:15017 E:15028 ||| NN
in  ||| S:15028 E:15031 ||| IN
systolic  ||| S:15031 E:15040 ||| JJ
blood  ||| S:15040 E:15046 ||| NN
pressure  ||| S:15046 E:15055 ||| NN
is  ||| S:15055 E:15066 ||| VBZ
associated  ||| S:15066 E:15077 ||| VBN
with  ||| S:15077 E:15082 ||| IN
an  ||| S:15082 E:15085 ||| DT
increased  ||| S:15085 E:15095 ||| JJ
relative  ||| S:15095 E:15104 ||| JJ
risk  ||| S:15104 E:15109 ||| NN
of  ||| S:15109 E:15112 ||| IN
only  ||| S:15112 E:15117 ||| RB
1.06  ||| S:15117 E:15122 ||| CD
to  ||| S:15122 E:15133 ||| TO
1.09  ||| S:15133 E:15138 ||| CD
[  ||| S:15138 E:15140 ||| -LRB-
23  ||| S:15140 E:15143 ||| CD
]  ||| S:15143 E:15145 ||| -RRB-
.  ||| S:15145 E:15147 ||| .
From  ||| S:15147 E:15152 ||| IN
available  ||| S:15152 E:15162 ||| JJ
data ||| S:15162 E:15166 ||| NNS
,  ||| S:15166 E:15168 ||| ,
it  ||| S:15168 E:15171 ||| PRP
appears  ||| S:15171 E:15179 ||| VBZ
that  ||| S:15179 E:15184 ||| IN
this  ||| S:15184 E:15197 ||| DT
average  ||| S:15197 E:15205 ||| JJ
difference  ||| S:15205 E:15216 ||| NN
in  ||| S:15216 E:15219 ||| IN
systolic  ||| S:15219 E:15228 ||| JJ
blood  ||| S:15228 E:15234 ||| NN
pressure  ||| S:15234 E:15243 ||| NN
is  ||| S:15243 E:15246 ||| VBZ
not  ||| S:15246 E:15250 ||| RB
large  ||| S:15250 E:15264 ||| JJ
enough  ||| S:15264 E:15271 ||| JJ
to  ||| S:15271 E:15274 ||| TO
double  ||| S:15274 E:15281 ||| VB
the  ||| S:15281 E:15285 ||| DT
average  ||| S:15285 E:15293 ||| JJ
incidence  ||| S:15293 E:15303 ||| NN
of  ||| S:15303 E:15306 ||| IN
CHF ||| S:15306 E:15309 ||| NNP
.  ||| S:15309 E:15319 ||| .
The  ||| S:15319 E:15323 ||| DT
literature  ||| S:15323 E:15334 ||| NN
suggests  ||| S:15334 E:15343 ||| VBZ
several  ||| S:15343 E:15351 ||| JJ
mechanisms  ||| S:15351 E:15362 ||| NNS
by  ||| S:15362 E:15365 ||| IN
which  ||| S:15365 E:15379 ||| WDT
peripheral  ||| S:15379 E:15390 ||| VBD
alpha-1  ||| S:15390 E:15398 ||| CD
antagonists  ||| S:15398 E:15410 ||| NNS
in  ||| S:15410 E:15413 ||| IN
general  ||| S:15413 E:15421 ||| JJ
and  ||| S:15421 E:15425 ||| CC
doxazosin  ||| S:15425 E:15435 ||| NN
in  ||| S:15435 E:15446 ||| IN
particular  ||| S:15446 E:15457 ||| JJ
might  ||| S:15457 E:15463 ||| MD
prove  ||| S:15463 E:15469 ||| VB
inferior  ||| S:15469 E:15478 ||| JJ
to  ||| S:15478 E:15481 ||| TO
other  ||| S:15481 E:15487 ||| JJ
types  ||| S:15487 E:15493 ||| NNS
of  ||| S:15493 E:15504 ||| IN
antihypertensive  ||| S:15504 E:15521 ||| JJ
therapy ||| S:15521 E:15528 ||| NN
.  ||| S:15528 E:15530 ||| .
They  ||| S:15530 E:15535 ||| PRP
are  ||| S:15535 E:15539 ||| VBP
associated  ||| S:15539 E:15550 ||| VBN
with  ||| S:15550 E:15555 ||| IN
a  ||| S:15555 E:15557 ||| DT
mild  ||| S:15557 E:15570 ||| JJ
volume  ||| S:15570 E:15577 ||| NN
expansion ||| S:15577 E:15586 ||| NN
,  ||| S:15586 E:15588 ||| ,
which  ||| S:15588 E:15594 ||| WDT
may  ||| S:15594 E:15598 ||| MD
precipitate  ||| S:15598 E:15610 ||| VB
the  ||| S:15610 E:15614 ||| DT
clinical  ||| S:15614 E:15631 ||| JJ
presentation  ||| S:15631 E:15644 ||| NN
of  ||| S:15644 E:15647 ||| IN
heart  ||| S:15647 E:15653 ||| NN
failure  ||| S:15653 E:15661 ||| NN
in  ||| S:15661 E:15664 ||| IN
those  ||| S:15664 E:15670 ||| DT
with  ||| S:15670 E:15675 ||| IN
subclinical  ||| S:15675 E:15695 ||| JJ
disease ||| S:15695 E:15702 ||| NN
.  ||| S:15702 E:15704 ||| .
If  ||| S:15704 E:15707 ||| IN
this  ||| S:15707 E:15712 ||| DT
is  ||| S:15712 E:15715 ||| VBZ
the  ||| S:15715 E:15719 ||| DT
mechanism  ||| S:15719 E:15729 ||| NN
responsible  ||| S:15729 E:15741 ||| JJ
for  ||| S:15741 E:15753 ||| IN
increasing  ||| S:15753 E:15764 ||| VBG
the  ||| S:15764 E:15768 ||| DT
incidence  ||| S:15768 E:15778 ||| NN
of  ||| S:15778 E:15781 ||| IN
CHF  ||| S:15781 E:15785 ||| NNP
in  ||| S:15785 E:15788 ||| IN
the  ||| S:15788 E:15792 ||| DT
ALLHAT  ||| S:15792 E:15799 ||| NNP
trial ||| S:15799 E:15804 ||| NN
,  ||| S:15804 E:15806 ||| ,
it  ||| S:15806 E:15817 ||| PRP
would  ||| S:15817 E:15823 ||| MD
be  ||| S:15823 E:15826 ||| VB
consistent  ||| S:15826 E:15837 ||| JJ
with  ||| S:15837 E:15842 ||| IN
the  ||| S:15842 E:15846 ||| DT
early  ||| S:15846 E:15852 ||| JJ
divergence  ||| S:15852 E:15863 ||| NN
of  ||| S:15863 E:15866 ||| IN
the  ||| S:15866 E:15878 ||| DT
Kaplan-Meier  ||| S:15878 E:15891 ||| JJ
curves  ||| S:15891 E:15898 ||| NN
in  ||| S:15898 E:15901 ||| IN
that  ||| S:15901 E:15906 ||| DT
study ||| S:15906 E:15911 ||| NN
.  ||| S:15911 E:15921 ||| .
Peripheral  ||| S:15921 E:15932 ||| NNP
alpha-1  ||| S:15932 E:15940 ||| NNP
antagonists  ||| S:15940 E:15952 ||| VBD
also  ||| S:15952 E:15957 ||| RB
cause  ||| S:15957 E:15963 ||| VB
neurohormonal  ||| S:15963 E:15985 ||| JJ
changes  ||| S:15985 E:15993 ||| NNS
during  ||| S:15993 E:16000 ||| IN
chronic  ||| S:16000 E:16008 ||| JJ
therapy ||| S:16008 E:16015 ||| NN
.  ||| S:16015 E:16017 ||| .
The  ||| S:16017 E:16021 ||| DT
long-term  ||| S:16021 E:16031 ||| JJ
ramifications  ||| S:16031 E:16053 ||| NNS
of  ||| S:16053 E:16056 ||| IN
these  ||| S:16056 E:16062 ||| DT
changes  ||| S:16062 E:16070 ||| NNS
for  ||| S:16070 E:16074 ||| IN
patients  ||| S:16074 E:16083 ||| NNS
being  ||| S:16083 E:16089 ||| VBG
treated  ||| S:16089 E:16097 ||| VBN
for  ||| S:16097 E:16109 ||| IN
hypertension  ||| S:16109 E:16122 ||| NNS
are  ||| S:16122 E:16126 ||| VBP
not  ||| S:16126 E:16130 ||| RB
known ||| S:16130 E:16135 ||| VBN
.  ||| S:16135 E:16137 ||| .
These  ||| S:16137 E:16143 ||| DT
drugs  ||| S:16143 E:16149 ||| NNS
appear  ||| S:16149 E:16156 ||| VBP
to  ||| S:16156 E:16159 ||| TO
cause  ||| S:16159 E:16173 ||| VB
increases  ||| S:16173 E:16183 ||| NNS
in  ||| S:16183 E:16186 ||| IN
norepinephrine ||| S:16186 E:16200 ||| NN
,  ||| S:16200 E:16202 ||| ,
and  ||| S:16202 E:16206 ||| CC
this  ||| S:16206 E:16211 ||| DT
increase  ||| S:16211 E:16220 ||| NN
may  ||| S:16220 E:16224 ||| MD
nullify  ||| S:16224 E:16240 ||| VB
the  ||| S:16240 E:16244 ||| DT
beneficial  ||| S:16244 E:16255 ||| JJ
effect  ||| S:16255 E:16262 ||| NN
of  ||| S:16262 E:16265 ||| IN
lowered  ||| S:16265 E:16273 ||| JJ
blood  ||| S:16273 E:16279 ||| NN
pressure  ||| S:16279 E:16288 ||| NN
on  ||| S:16288 E:16291 ||| IN
the  ||| S:16291 E:16303 ||| DT
occurrence  ||| S:16303 E:16314 ||| NN
of  ||| S:16314 E:16317 ||| IN
CHF ||| S:16317 E:16320 ||| NNP
.  ||| S:16320 E:16322 ||| .
Not  ||| S:16322 E:16326 ||| RB
only  ||| S:16326 E:16331 ||| RB
are  ||| S:16331 E:16335 ||| VBP
increased  ||| S:16335 E:16345 ||| VBN
plasma  ||| S:16345 E:16360 ||| NNS
catecholamines  ||| S:16360 E:16375 ||| VBP
a  ||| S:16375 E:16377 ||| DT
central  ||| S:16377 E:16385 ||| JJ
feature  ||| S:16385 E:16393 ||| NN
in  ||| S:16393 E:16396 ||| IN
heart  ||| S:16396 E:16402 ||| NN
failure ||| S:16402 E:16409 ||| NN
,  ||| S:16409 E:16411 ||| ,
they  ||| S:16411 E:16416 ||| PRP
are  ||| S:16416 E:16428 ||| VBP
now  ||| S:16428 E:16432 ||| RB
a  ||| S:16432 E:16434 ||| DT
recommended  ||| S:16434 E:16446 ||| JJ
target  ||| S:16446 E:16453 ||| NN
for  ||| S:16453 E:16457 ||| IN
effective  ||| S:16457 E:16467 ||| JJ
life-prolonging  ||| S:16467 E:16491 ||| JJ
therapy  ||| S:16491 E:16499 ||| NN
[  ||| S:16499 E:16501 ||| -LRB-
24  ||| S:16501 E:16504 ||| CD
25  ||| S:16504 E:16507 ||| CD
26  ||| S:16507 E:16510 ||| CD
]  ||| S:16510 E:16512 ||| -RRB-
.  ||| S:16512 E:16522 ||| .
Given  ||| S:16522 E:16528 ||| VBN
that  ||| S:16528 E:16533 ||| IN
doxazosin  ||| S:16533 E:16543 ||| NN
is  ||| S:16543 E:16546 ||| VBZ
not  ||| S:16546 E:16550 ||| RB
as  ||| S:16550 E:16553 ||| IN
effective  ||| S:16553 E:16563 ||| JJ
as  ||| S:16563 E:16574 ||| IN
chlorthalidone  ||| S:16574 E:16589 ||| NN
in  ||| S:16589 E:16592 ||| IN
reducing  ||| S:16592 E:16601 ||| VBG
the  ||| S:16601 E:16605 ||| DT
cardiovascular  ||| S:16605 E:16620 ||| JJ
complications  ||| S:16620 E:16642 ||| NNS
of  ||| S:16642 E:16645 ||| IN
hypertension ||| S:16645 E:16657 ||| NN
,  ||| S:16657 E:16659 ||| ,
several  ||| S:16659 E:16667 ||| JJ
questions  ||| S:16667 E:16677 ||| NNS
remain ||| S:16677 E:16683 ||| VBP
.  ||| S:16683 E:16685 ||| .
There  ||| S:16685 E:16691 ||| EX
is  ||| S:16691 E:16694 ||| VBZ
still  ||| S:16694 E:16700 ||| RB
a  ||| S:16700 E:16710 ||| DT
paucity  ||| S:16710 E:16718 ||| NN
of  ||| S:16718 E:16721 ||| IN
information  ||| S:16721 E:16733 ||| NN
regarding  ||| S:16733 E:16743 ||| VBG
the  ||| S:16743 E:16747 ||| DT
absolute  ||| S:16747 E:16756 ||| JJ
risk  ||| S:16756 E:16769 ||| NN
reduction  ||| S:16769 E:16779 ||| NN
for  ||| S:16779 E:16783 ||| IN
clinical  ||| S:16783 E:16792 ||| JJ
heart  ||| S:16792 E:16798 ||| NN
failure  ||| S:16798 E:16806 ||| NN
or  ||| S:16806 E:16809 ||| CC
other  ||| S:16809 E:16823 ||| JJ
cardiovascular  ||| S:16823 E:16838 ||| JJ
events  ||| S:16838 E:16845 ||| NNS
afforded  ||| S:16845 E:16854 ||| VBN
by  ||| S:16854 E:16857 ||| IN
peripheral  ||| S:16857 E:16868 ||| JJ
alpha-1  ||| S:16868 E:16884 ||| CD
antagonists  ||| S:16884 E:16896 ||| NNS
in  ||| S:16896 E:16899 ||| IN
a  ||| S:16899 E:16901 ||| DT
variety  ||| S:16901 E:16909 ||| NN
of  ||| S:16909 E:16912 ||| IN
populations ||| S:16912 E:16923 ||| NNS
.  ||| S:16923 E:16925 ||| .
Differentiation  ||| S:16925 E:16941 ||| NNP
of  ||| S:16941 E:16952 ||| IN
the  ||| S:16952 E:16956 ||| DT
mechanism  ||| S:16956 E:16966 ||| NN
for  ||| S:16966 E:16970 ||| IN
reduced  ||| S:16970 E:16978 ||| JJ
protection  ||| S:16978 E:16989 ||| NN
compared  ||| S:16989 E:16998 ||| VBN
to  ||| S:16998 E:17001 ||| TO
diuretics  ||| S:17001 E:17019 ||| NNS
would  ||| S:17019 E:17025 ||| MD
be  ||| S:17025 E:17028 ||| VB
interesting  ||| S:17028 E:17040 ||| JJ
but  ||| S:17040 E:17044 ||| CC
difficult  ||| S:17044 E:17054 ||| JJ
to  ||| S:17054 E:17057 ||| TO
accomplish ||| S:17057 E:17067 ||| VB
.  ||| S:17067 E:17069 ||| .
For  ||| S:17069 E:17073 ||| IN
heart  ||| S:17073 E:17087 ||| NN
failure  ||| S:17087 E:17095 ||| NN
in  ||| S:17095 E:17098 ||| IN
particular ||| S:17098 E:17108 ||| JJ
,  ||| S:17108 E:17110 ||| ,
the  ||| S:17110 E:17114 ||| DT
increase  ||| S:17114 E:17123 ||| NN
in  ||| S:17123 E:17126 ||| IN
symptomatic  ||| S:17126 E:17138 ||| JJ
episodes  ||| S:17138 E:17155 ||| NNS
of  ||| S:17155 E:17158 ||| IN
CHF  ||| S:17158 E:17162 ||| NNP
may  ||| S:17162 E:17166 ||| MD
be  ||| S:17166 E:17169 ||| VB
due  ||| S:17169 E:17173 ||| JJ
to  ||| S:17173 E:17176 ||| TO
hemodynamic  ||| S:17176 E:17188 ||| VB
effects  ||| S:17188 E:17196 ||| NNS
of  ||| S:17196 E:17199 ||| IN
doxazosin  ||| S:17199 E:17217 ||| JJ
unmasking  ||| S:17217 E:17227 ||| JJ
incipient  ||| S:17227 E:17237 ||| JJ
heart  ||| S:17237 E:17243 ||| NN
failure ||| S:17243 E:17250 ||| NN
,  ||| S:17250 E:17252 ||| ,
direct  ||| S:17252 E:17259 ||| JJ
myocardial  ||| S:17259 E:17278 ||| JJ
injury ||| S:17278 E:17284 ||| NN
,  ||| S:17284 E:17286 ||| ,
or  ||| S:17286 E:17289 ||| CC
both ||| S:17289 E:17293 ||| DT
.  ||| S:17293 E:17295 ||| .
Chronic  ||| S:17295 E:17303 ||| JJ
volume  ||| S:17303 E:17310 ||| NN
loading  ||| S:17310 E:17318 ||| NN
may  ||| S:17318 E:17322 ||| MD
not  ||| S:17322 E:17326 ||| RB
only  ||| S:17326 E:17331 ||| RB
unmask  ||| S:17331 E:17346 ||| VB
subclinical  ||| S:17346 E:17358 ||| JJ
ventricular  ||| S:17358 E:17370 ||| JJ
dysfunction ||| S:17370 E:17381 ||| NN
,  ||| S:17381 E:17383 ||| ,
but  ||| S:17383 E:17387 ||| CC
may  ||| S:17387 E:17391 ||| MD
possibly  ||| S:17391 E:17408 ||| RB
contribute  ||| S:17408 E:17419 ||| VB
to  ||| S:17419 E:17422 ||| TO
worsening  ||| S:17422 E:17432 ||| VB
ventricular  ||| S:17432 E:17444 ||| JJ
function  ||| S:17444 E:17453 ||| NN
over  ||| S:17453 E:17458 ||| IN
time ||| S:17458 E:17462 ||| NN
.  ||| S:17462 E:17472 ||| .
Whatever  ||| S:17472 E:17481 ||| JJ
mechanisms  ||| S:17481 E:17492 ||| NNS
were  ||| S:17492 E:17497 ||| VBD
responsible  ||| S:17497 E:17509 ||| JJ
for  ||| S:17509 E:17513 ||| IN
the  ||| S:17513 E:17517 ||| DT
heart  ||| S:17517 E:17531 ||| NN
failure  ||| S:17531 E:17539 ||| NN
findings  ||| S:17539 E:17548 ||| NNS
in  ||| S:17548 E:17551 ||| IN
ALLHAT ||| S:17551 E:17557 ||| NNP
,  ||| S:17557 E:17559 ||| ,
the  ||| S:17559 E:17563 ||| DT
results  ||| S:17563 E:17571 ||| NNS
support  ||| S:17571 E:17579 ||| VBP
the  ||| S:17579 E:17583 ||| DT
current  ||| S:17583 E:17599 ||| JJ
national  ||| S:17599 E:17608 ||| JJ
recommendations  ||| S:17608 E:17624 ||| NNS
to  ||| S:17624 E:17627 ||| TO
use  ||| S:17627 E:17631 ||| VB
low-dose  ||| S:17631 E:17640 ||| JJ
diuretics  ||| S:17640 E:17650 ||| NN
or  ||| S:17650 E:17661 ||| CC
beta-blockers  ||| S:17661 E:17675 ||| JJ
as  ||| S:17675 E:17678 ||| IN
first  ||| S:17678 E:17684 ||| JJ
line  ||| S:17684 E:17689 ||| NN
agents  ||| S:17689 E:17696 ||| NNS
for  ||| S:17696 E:17700 ||| IN
the  ||| S:17700 E:17704 ||| DT
pharmacologic  ||| S:17704 E:17726 ||| JJ
treatment  ||| S:17726 E:17736 ||| NN
of  ||| S:17736 E:17739 ||| IN
uncomplicated  ||| S:17739 E:17753 ||| JJ
hypertension ||| S:17753 E:17765 ||| NN
.  ||| S:17765 E:17789 ||| .
Competing  ||| S:17789 E:17799 ||| VBG
Interests  ||| S:17799 E:17817 ||| NNP
Dr.  ||| S:17817 E:17821 ||| NNP
Psaty  ||| S:17821 E:17827 ||| NNP
was  ||| S:17827 E:17831 ||| VBD
a  ||| S:17831 E:17833 ||| DT
Merck ||| S:17833 E:17838 ||| NNP
/ ||| S:17838 E:17839 ||| NNP
SER  ||| S:17839 E:17843 ||| NNP
Clinical  ||| S:17843 E:17852 ||| NNP
Epidemiology  ||| S:17852 E:17865 ||| NNP
Fellow  ||| S:17865 E:17880 ||| NNP
( ||| S:17880 E:17881 ||| -LRB-
co-sponsored  ||| S:17881 E:17894 ||| VBN
by  ||| S:17894 E:17897 ||| IN
the  ||| S:17897 E:17901 ||| DT
Merck  ||| S:17901 E:17907 ||| NNP
Co ||| S:17907 E:17909 ||| NNP
.  ||| S:17909 E:17911 ||| .
Foundation ||| S:17911 E:17921 ||| NNP
,  ||| S:17921 E:17923 ||| ,
Rahway ||| S:17923 E:17929 ||| NNP
,  ||| S:17929 E:17931 ||| ,
NJ ||| S:17931 E:17933 ||| NNP
,  ||| S:17933 E:17935 ||| ,
and  ||| S:17935 E:17947 ||| CC
the  ||| S:17947 E:17951 ||| DT
Society  ||| S:17951 E:17959 ||| NNP
for  ||| S:17959 E:17963 ||| IN
Epidemiologic  ||| S:17963 E:17977 ||| NNP
Research ||| S:17977 E:17985 ||| NNP
,  ||| S:17985 E:17987 ||| ,
Baltimore ||| S:17987 E:17996 ||| NNP
,  ||| S:17996 E:17998 ||| ,
MD ||| S:17998 E:18000 ||| NNP
) ||| S:18000 E:18001 ||| -RRB-
,  ||| S:18001 E:18003 ||| ,
and  ||| S:18003 E:18015 ||| CC
a  ||| S:18015 E:18017 ||| DT
member  ||| S:18017 E:18024 ||| NN
of  ||| S:18024 E:18027 ||| IN
the  ||| S:18027 E:18031 ||| DT
Events  ||| S:18031 E:18038 ||| NNP
Committee  ||| S:18038 E:18048 ||| NNP
of  ||| S:18048 E:18051 ||| IN
the  ||| S:18051 E:18055 ||| DT
HERS  ||| S:18055 E:18060 ||| NNP
trial  ||| S:18060 E:18066 ||| NN
funded  ||| S:18066 E:18081 ||| VBN
by  ||| S:18081 E:18084 ||| IN
Wyeth  ||| S:18084 E:18090 ||| NNP
Ay  ||| S:18090 E:18093 ||| NNP
erst ||| S:18093 E:18097 ||| NN
.  ||| S:18097 E:18114 ||| .
